<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
    <title>Compound GLP: compounded semaglutide and tirzepatide, examined</title>
    <subtitle>Compounded GLP-1 drugs explained from the law and the evidence: 503A and 503B pharmacies, the FDA shortage list and its end, salt forms, dosing errors, lawsuits and how to judge a compounder.</subtitle>
    <link rel="self" type="application/atom+xml" href="https://compoundglp.com/atom.xml"/>
    <link rel="alternate" type="text/html" href="https://compoundglp.com"/>
    <generator uri="https://www.getzola.org/">Zola</generator>
    <updated>2026-11-01T00:00:00+00:00</updated>
    <id>https://compoundglp.com/atom.xml</id>
    <entry xml:lang="en">
        <title>503A vs 503B: The Two Kinds of Compounder the Law Allows</title>
        <published>2026-11-01T00:00:00+00:00</published>
        <updated>2026-11-01T00:00:00+00:00</updated>
        
        <author>
          <name>
            
              Unknown
            
          </name>
        </author>
        
        <link rel="alternate" type="text/html" href="https://compoundglp.com/503a-vs-503b/"/>
        <id>https://compoundglp.com/503a-vs-503b/</id>
        
        <content type="html" xml:base="https://compoundglp.com/503a-vs-503b/">&lt;p&gt;I spent part of this week with one sentence from a compliance guide, and I have come to believe it contains most of American drug compounding in about fifty words. The guide is titled “503A vs. 503B: A Quick-Guide to Compounding Pharmacy Designations &amp;amp; Regulations,” and here is the sentence: “503A pharmacies compound only against patient-specific prescriptions and must comply with USP &amp;lt;795&amp;gt; and &amp;lt;797&amp;gt; plus state board rules; 503B outsourcing facilities may produce large batches without patient-specific prescriptions but must comply with full CGMP under 21 CFR Parts 210 and 211.”&lt;&#x2F;p&gt;
&lt;p&gt;The plain answer first. A 503a pharmacy is a state-licensed pharmacy (or a federal facility, or a licensed physician) that mixes a drug for a particular, named patient on a prescription, and it is overseen mainly by its state board of pharmacy rather than the FDA. A 503B outsourcing facility is the other kind of compounder the law allows: it may make large batches without individual prescriptions, and in exchange it registers with the FDA, follows manufacturing-grade rules called CGMP, and gets inspected. That is the summary. The sentence is more interesting than the summary, so let’s read it like a contract.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-a-503a-pharmacy-is-allowed-to-do-clause-by-clause&quot;&gt;What a 503A pharmacy is allowed to do, clause by clause&lt;&#x2F;h2&gt;
&lt;p&gt;“503A pharmacies compound.” Fine. Under the statute, that compounding has to be “performed by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed physician,” as the law firm ArentFox Schiff summarizes Section 503A. So far this is just a description of a pharmacist doing pharmacist stuff.&lt;&#x2F;p&gt;
&lt;p&gt;“Only against patient-specific prescriptions.” I love the word “against.” It is the word you use for drawing against a credit line, and it fits: every vial a 503A pharmacy makes is drawn against a specific prescription for a specific person, and the prescription is sort of the collateral. No prescription, no vial. The guide’s other formulation is that 503A pharmacies “are designated as those that compound according to prescriptions specific to particular patients,” which is the same idea with less banking in it.&lt;&#x2F;p&gt;
&lt;p&gt;“Must comply with USP &amp;lt;795&amp;gt; and &amp;lt;797&amp;gt; plus state board rules.” Those are the standards for nonsterile and sterile compounding, plus whatever the state board wants. Now notice what is missing from the clause.&lt;&#x2F;p&gt;
&lt;p&gt;The FDA.&lt;&#x2F;p&gt;
&lt;p&gt;That absence is the whole point. A 503A pharmacy is not required to register with the FDA, and a pharmacy compounding under 503A for a patient-specific prescription is exempt from the federal CGMP framework in 21 CFR Parts 210 and 211. Read that exemption literally, though, and it has a condition baked in: it applies to compounding “for a patient-specific prescription.” The exemption does not belong to the building. It travels with the prescription.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;why-the-patient-s-name-does-so-much-work-at-a-503a-pharmacy&quot;&gt;Why the patient’s name does so much work at a 503A pharmacy&lt;&#x2F;h2&gt;
&lt;p&gt;The intuitive way to describe this is that 503A is the small compounder and 503B is the big one. Actually, no. The sentence never says small. It says patient-specific, and those are different words that happen to point in the same direction most of the time.&lt;&#x2F;p&gt;
&lt;p&gt;Here is an invented example, clearly made up. Imagine a 503A pharmacy in a mid-sized city where, through some combination of telehealth and enthusiasm, 40,000 residents each hold a valid prescription for the same compounded injection. Every vial is labeled with a real person’s name. Every vial is drawn against a real prescription. The pharmacy runs three shifts, buys a second building, and installs a conveyor belt, and each item on the conveyor belt is still, technically, a bespoke preparation for Ms. Jane Doe of Elm Street (and her 39,999 neighbors). Literally, the clause is satisfied. In spirit, the place is presumably a factory that happens to hold a pharmacy license.&lt;&#x2F;p&gt;
&lt;p&gt;Where the law draws a numerical line on 503A volume is something the sources I’m working from do not settle; they describe the limit as the prescription requirement itself rather than as a number of units. The structural point holds either way: the 503A deal is that you get light federal oversight because you are doing something small and personal, and the prescription is the proof that it is small and personal. It is the cheapest possible compliance document. Somebody has to write it, though.&lt;&#x2F;p&gt;
&lt;p&gt;The everyday version is the difference between a diner cook and a frozen-pizza plant. Nobody inspects the diner cook’s process with the same rulebook as the pizza plant, because the cook is making one pizza for the person in booth four (who has never once asked to see a stability study). If the cook started shipping 40,000 pizzas a week, people would start asking pizza-plant questions.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-a-503b-outsourcing-facility-gets-for-its-paperwork&quot;&gt;What a 503B outsourcing facility gets for its paperwork&lt;&#x2F;h2&gt;
&lt;p&gt;Now the second half. “503B outsourcing facilities may produce large batches.” The verb is “may,” which is permission, and “large batches” is the thing 503A could not quite do. “Without patient-specific prescriptions”: elsewhere the guide says “with or without prescriptions,” which is more accurate and also funnier, because it means the prescription has gone from collateral to optional.&lt;&#x2F;p&gt;
&lt;p&gt;“But must comply with full CGMP under 21 CFR Parts 210 and 211.” That “but” is the price. Section 501(a)(2)(B) of the Food, Drug, and Cosmetic Act requires outsourcing facilities to follow current good manufacturing practice, and they must also register with the FDA and submit to regular inspections, on top of state board rules. In exchange for giving up the patient’s name, they take on a manufacturer’s obligations.&lt;&#x2F;p&gt;
&lt;p&gt;Those obligations get specific. The FDA’s draft CGMP guidance for outsourcing facilities expects beyond-use dates (roughly, the date after which you should not use the stuff) to be supported by formulation-specific stability data, rather than the default categories a 503A pharmacy may rely on under USP &amp;lt;797&amp;gt;. (I have now read more about beyond-use dates than any person who writes jokes for a living probably should.) So the 503A pharmacist can look up a default date, and the 503B facility has to prove its date. I feel like I can hear the auditor: “Great, love the label, now show me the stability study for this exact formulation.”&lt;&#x2F;p&gt;
&lt;p&gt;One more thing the clause leaves out: approval. 503B facilities, for all their registration and inspection, “still do not produce FDA-approved medications.” They also face a bulks-list requirement for the raw ingredients they compound from, and tirzepatide, for instance, is not on the FDA’s Bulks List for 503B facilities or its Interim Bulks List. Big batches, manufacturing rules, and still not an approved drug.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-neither-kind-of-compounder-is-allowed-to-copy&quot;&gt;What neither kind of compounder is allowed to copy&lt;&#x2F;h2&gt;
&lt;p&gt;Both halves of the sentence share an unwritten clause: neither 503A nor 503B generally lets a compounder make a drug that is a copy of a commercially available, FDA-approved product. The exception is shortage. While the approved drug is on the FDA’s shortage list, compounders may fill the gap, and ArentFox Schiff’s description of the 503B version has a phrase worth reading literally: the drug must be on the list “at the time of compounding, distribution, and dispensing.” Three moments, all of which must be true. Not “once” or “recently.” (That is a lot to ask of a list.)&lt;&#x2F;p&gt;
&lt;p&gt;That is how the GLP-1 compounding boom worked and how it ended, which other articles on this site cover in detail. The short version is that the FDA’s February 21, 2025 declaratory order resolved the semaglutide injection shortage, and then the agency exercised what lawyers call enforcement discretion, a phrase that sounds like something you would want from a hotel concierge. 503A pharmacies got 60 days, to April 22, 2025. 503B facilities got 90, to May 22, 2025.&lt;&#x2F;p&gt;
&lt;p&gt;The gap is sort of revealing. The bigger, more regulated compounder got the longer runway, presumably because it had bigger batches and more customers to unwind. And in May 2026 the FDA proposed a rule that, if finalized, would close the last remaining pathway for large-scale 503B compounding of semaglutide, tirzepatide and liraglutide. Big machine, slow brakes.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;why-everyone-in-this-sentence-is-acting-sensibly&quot;&gt;Why everyone in this sentence is acting sensibly&lt;&#x2F;h2&gt;
&lt;p&gt;It is tempting to read all this as dumb bureaucracy, but each party is doing the reasonable thing from where it sits. The FDA does not want to inspect every pharmacist making one cream for one patient, and it very much wants to inspect anything that looks like a factory. Pharmacies want to serve patients who show up with prescriptions, and outsourcing facilities want scale and will accept the inspections as the cost of it. Patients during a shortage wanted the drug that was unavailable, lol, which is not a complicated position.&lt;&#x2F;p&gt;
&lt;p&gt;The result is a regulatory regime that sorts compounders by one document. With it, you are a pharmacy. Without it, you are a manufacturer, almost.&lt;&#x2F;p&gt;
&lt;p&gt;The prescription is the whole difference.&lt;&#x2F;p&gt;
</content>
        
    </entry>
    <entry xml:lang="en">
        <title>Inside a 503B Outsourcing Facility</title>
        <published>2026-11-01T00:00:00+00:00</published>
        <updated>2026-11-01T00:00:00+00:00</updated>
        
        <author>
          <name>
            
              Unknown
            
          </name>
        </author>
        
        <link rel="alternate" type="text/html" href="https://compoundglp.com/503b-outsourcing-facility/"/>
        <id>https://compoundglp.com/503b-outsourcing-facility/</id>
        
        <content type="html" xml:base="https://compoundglp.com/503b-outsourcing-facility/">&lt;p&gt;A 503B outsourcing facility is a pharmacy that has agreed to be inspected like a drug factory in exchange for being allowed to behave a bit like one. It registers with the FDA, follows the federal manufacturing rules called current good manufacturing practice (CGMP, under 21 CFR Parts 210 and 211), and submits to regular FDA inspections. In return it may produce large batches of drugs without a prescription for each individual patient. What it makes is still not an FDA-approved drug.&lt;&#x2F;p&gt;
&lt;p&gt;The catch is what it may make. When a 503B outsourcing facility compounds from bulk drug substances (the raw powder, basically), the drug generally has to appear on the FDA’s 503B bulks list or on the FDA drug shortage list. Separately, the law generally prohibits compounders from making a copy of a commercially available, approved product unless that product is on the shortage list. That is why compounded semaglutide and tirzepatide went from a large business to a wind-down. The shortages ended, and the GLP-1s were on neither list.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;start-with-one-pharmacist-and-one-prescription&quot;&gt;Start with one pharmacist and one prescription&lt;&#x2F;h2&gt;
&lt;p&gt;Here is an invented pharmacist, Dana, who exists only for this paragraph and the next few. A doctor sends her a prescription for a patient who needs a drug in a form nobody sells (a different strength, no dye, that sort of thing). Dana mixes it. Under 503A, a qualifying compounded product like that is exempt from CGMP, from the federal labeling requirement and from new drug approval. That’s fine. One patient, one vial.&lt;&#x2F;p&gt;
&lt;p&gt;Then Dana notices the same prescription arrives every Tuesday, so she makes ten on Monday. In some sense she is now forecasting demand, which is what manufacturers do, but the names still show up eventually.&lt;&#x2F;p&gt;
&lt;p&gt;Then a hospital calls. “Hey, can you just send us 500 syringes? We’ll match them to patients as they come in.” Now there are no names. Dana is making a product and shipping it to a customer who will decide later who gets it.&lt;&#x2F;p&gt;
&lt;p&gt;Then it is 50,000 vials a month, made from bulk powder, shipped to clinics in a dozen states, none of it tied to any patient. This is If You Give a Mouse a Cookie, except the cookie is a sterile injectable and the mouse is a hospital purchasing department. At the end of the road Dana runs a pharmaceutical plant whose product never went through an approval, operating under rules written for someone mixing one cream at a counter.&lt;&#x2F;p&gt;
&lt;p&gt;You would think the law forbids that endpoint. It mostly said: fine, register.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-registering-as-a-503b-outsourcing-facility-actually-means&quot;&gt;What registering as a 503B outsourcing facility actually means&lt;&#x2F;h2&gt;
&lt;p&gt;Put plainly, the arrangement is this: a pharmacy may stop asking for the prescription if it agrees to be treated like a factory. The official name for a pharmacy that takes that arrangement is an outsourcing facility, under Section 503B of the Food, Drug, and Cosmetic Act. A 503A pharmacy compounds only against patient-specific prescriptions and answers to USP &amp;lt;795&amp;gt; and &amp;lt;797&amp;gt; plus its state board. A 503B facility may make large batches with or without prescriptions, but must comply with full CGMP under Parts 210 and 211, on top of state board of pharmacy rules.&lt;&#x2F;p&gt;
&lt;p&gt;So registration is a trade. You give up the light rulebook and get the heavy one, plus inspectors. The product does not become approved along the way (the facility gets inspected, the drug in the vial does not get reviewed the way an approved drug does).&lt;&#x2F;p&gt;
&lt;p&gt;There is a second registration for facilities that handle controlled substances, and it rests on a point that deserves to be set out with proper formality. Let it be entered into the record, for the avoidance of doubt, that making a great many of something is a different activity from making one of it. The DEA concurs. A 503B facility handling controlled substances generally must register as a manufacturer rather than a dispenser, because batch production falls outside the practitioner exclusion in 21 U.S.C. 802(15). If you make it in batches, you are a manufacturer. Hard to argue.&lt;&#x2F;p&gt;
&lt;p&gt;On the reporting a facility sends to the FDA, the sources here say very little, so I won’t fill it in. What they do describe is the paperwork the FDA sends back, which comes up below.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;the-factory-rules-cgmp-stability-data-and-the-clean-room&quot;&gt;The factory rules: CGMP, stability data and the clean room&lt;&#x2F;h2&gt;
&lt;p&gt;Section 501(a)(2)(B) of the FD&amp;amp;C Act is what requires outsourcing facilities to follow CGMP. Which CGMP, though? A Health Law Alliance article by Diana Yastrovskaya, published August 7, 2026, says the FDA applies Parts 210 and 211 “until it finalizes CGMP regulations written specifically for outsourcing facilities,” and those were still in draft. The FDA has been releasing guidances on what it expects of 503B facility space since at least October 2017. The bespoke rulebook is still being written. In the meantime, the general manufacturing one applies.&lt;&#x2F;p&gt;
&lt;p&gt;What that means in practice: every process gets validated. Before a new product goes to market, the facility must produce multiple batches and submit them for testing and stability. Beyond-use dates (how long the vial is good for) are expected to rest on stability data for that specific formulation, rather than the default categories a 503A pharmacy may lean on under USP &amp;lt;797&amp;gt;. A 503A pharmacy can look up a shelf life. A 503B has to earn it.&lt;&#x2F;p&gt;
&lt;p&gt;Then the clean room. Under 21 CFR 211.42(c)(10)(iv), an outsourcing facility must keep “a system for monitoring environmental conditions in its aseptic processing area on an ongoing basis.” The federal government, in other words, would like to know what goes on in that room at all hours, and it would like it written down. (I have now read Part 211 for fun, which is the sort of thing I mention at parties right before people find someone else to talk to.)&lt;&#x2F;p&gt;
&lt;p&gt;Inspectors write down what they find on Form FDA 483. Facility control system failures ranked second among 483 observation categories for outsourcing facilities, at roughly 13 percent. Past the 483 there is the warning letter; the FDA issued one on March 20, 2026, to RC Outsourcing, LLC, an Ohio outsourcing facility.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;the-two-lists-that-decide-what-gets-made&quot;&gt;The two lists that decide what gets made&lt;&#x2F;h2&gt;
&lt;p&gt;None of this factory apparatus decides what the factory may produce. That is the job of two lists. Outsourcing facilities face a bulks-list requirement in addition to CGMP when compounding from bulk drug substances. The other route is the shortage exception, which lets a facility compound large volumes from bulk without patient prescriptions if the drug is on the FDA’s shortage list at the time of compounding, distribution, and dispensing. All three, not just the first.&lt;&#x2F;p&gt;
&lt;p&gt;The shortage exception works like using a neighbor’s parking spot while they are out of town. Perfectly fine while the spot is empty. When their car comes back, you move yours. The FDA, being polite, gave people some time to move the car, or whatever, which is the next section.&lt;&#x2F;p&gt;
&lt;p&gt;So the industry tried the other list. In 2024 the Outsourcing Facilities Association nominated semaglutide, tirzepatide, and liraglutide for the 503B bulks list. The problem is what counts. According to the law firm ArentFox Schiff, when the FDA assesses clinical need for the bulks list, it “does not consider supply issues such as backorders, convenience in administering a compounded drug product, or the cost of the compounded product compared with an FDA-approved drug.” Which removes, I suppose, most of the reasons anyone wanted compounded GLP-1s. Tirzepatide is on neither the bulks list nor the interim bulks list. At the time one source wrote, semaglutide was on neither the bulks list nor the shortage list.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;how-the-glp-1-batches-ended-and-how-the-last-door-might-close&quot;&gt;How the GLP-1 batches ended, and how the last door might close&lt;&#x2F;h2&gt;
&lt;p&gt;Pharmacy Times put the history in one line: “503B outsourcing facility mass compounding of GLP-1 products was generally only permitted during shortages of the FDA-approved GLP-1 products.” The shortages ended, so that was that.&lt;&#x2F;p&gt;
&lt;p&gt;For semaglutide, the FDA issued a declaratory order on February 21, 2025, resolving the injectable shortage. It gave 503A pharmacies until April 22, 2025, and 503B facilities 90 calendar days, until May 22, 2025, during which it would not take enforcement action. On March 10, 2025, FDA guidance clarified that both kinds of compounder must stop or risk enforcement. Tirzepatide’s grace period for 503B facilities ended earlier, on March 19, 2025. Batches of semaglutide made before May 22 could still be sold until the expiration date on each vial, which I guess is the regulatory version of finishing your drink before you leave.&lt;&#x2F;p&gt;
&lt;p&gt;Then, in May 2026, the FDA made a proposal that, if finalized, would close the last remaining pathway for large-scale 503B compounding of semaglutide, tirzepatide, and liraglutide. Whether it has been finalized, I don’t know; the sources here don’t settle it.&lt;&#x2F;p&gt;
&lt;p&gt;Which leaves the 503B facility where Dana’s story ended: registered, inspected, validated, monitored around the clock. Ready to make anything. It is a very well-run factory that is not allowed to make the thing everyone wanted.&lt;&#x2F;p&gt;
</content>
        
    </entry>
    <entry xml:lang="en">
        <title>What Happened When the GLP-1 Shortages Ended</title>
        <published>2026-11-01T00:00:00+00:00</published>
        <updated>2026-11-01T00:00:00+00:00</updated>
        
        <author>
          <name>
            
              Unknown
            
          </name>
        </author>
        
        <link rel="alternate" type="text/html" href="https://compoundglp.com/after-the-shortage-ended/"/>
        <id>https://compoundglp.com/after-the-shortage-ended/</id>
        
        <content type="html" xml:base="https://compoundglp.com/after-the-shortage-ended/">&lt;p&gt;On February 21, 2025, the FDA officially declared that there was enough semaglutide. (Technically it declared that the shortage had ended, which is the same announcement in government voice.) For a lot of businesses this was bad news. They had been allowed to sell semaglutide at all only because there wasn’t enough of it.&lt;&#x2F;p&gt;
&lt;p&gt;So, is compounded semaglutide still legal? Narrowly, yes. Broadly, no. A state-licensed 503A pharmacy can still compound it for an individual patient if the prescriber documents a clinically significant difference from the commercial product. A 503B outsourcing facility can only use bulk semaglutide if it appears on the FDA’s bulk substances list or on the shortage list, and as of one source’s writing it was on neither. What compounders lost was the broad permission to mass-produce near-identical copies of the brand-name product, which was most of the business.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;how-a-shortage-made-copying-legal-in-the-first-place&quot;&gt;How a shortage made copying legal in the first place&lt;&#x2F;h2&gt;
&lt;p&gt;Here is the rule underneath all of this. Compounding a copy of an FDA-approved drug is ordinarily prohibited. But sections 503A and 503B of the Food, Drug, and Cosmetic Act carve out an exception for shortages. Under 503B, outsourcing facilities can make large volumes from bulk drug substances, without individual prescriptions, as long as the drug is on the shortage list at the time of compounding, distribution and dispensing. (That last clause will matter.)&lt;&#x2F;p&gt;
&lt;p&gt;Semaglutide and tirzepatide went on the list in 2022, when demand outstripped supply, and compounders came in. The result, in the words of law firm ArentFox Schiff, was a “multibillion-dollar sub-industry.” By October 2024, millions of patients were estimated to be taking compounded GLP-1s, and at the 2024 peak nearly 1 in 3 Americans on a GLP-1 said they got it from a compounding pharmacy. Compounded semaglutide typically cost $150 to $400 a month. None of it was reviewed by the FDA for safety or efficacy, because that is not what the exception does. The exception fills gaps.&lt;&#x2F;p&gt;
&lt;p&gt;Then the gap closed.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;the-dumb-version-of-ending-a-shortage&quot;&gt;The dumb version of ending a shortage&lt;&#x2F;h2&gt;
&lt;p&gt;The dumb version goes like this. The FDA looks at supply, decides there is enough, and takes the drug off the list. The exception disappears. Compounders stop. Patients get brand semaglutide, or nothing, or something else.&lt;&#x2F;p&gt;
&lt;p&gt;That is how a light switch works. It is not how a multibillion-dollar sub-industry works, because that has inventory, open prescriptions, patients partway through treatment, and lawyers. (Lots of lawyers.) It also matters who supplied the data behind the switch. For semaglutide, the FDA relied heavily on Novo Nordisk’s production, inventory, supply, wholesaler and projected demand information. For tirzepatide, it reviewed Eli Lilly’s expanded manufacturing capacity alongside input from compounders, patients, telehealth companies and others.&lt;&#x2F;p&gt;
&lt;p&gt;You can sort of see why the compounders did not just say “ah, fair enough.” Industry groups challenged the 503B enforcement deadline and got injunctions that temporarily prevented a complete shutdown of semaglutide compounding. How far those went, and for how long, is not settled by anything I have here.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;the-grace-period-version-with-beyond-use-dates&quot;&gt;The grace period version, with beyond-use dates&lt;&#x2F;h2&gt;
&lt;p&gt;So the real version is longer. The FDA set phased enforcement deadlines for compounders to wind down. For tirzepatide, the grace period ended February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B outsourcing facilities. For semaglutide, 503B facilities that made product before May 22, 2025 could sell those batches until the expiration date on each vial. In general, product compounded and dispensed before the deadline can be used through its beyond-use date. New compounding after the window closes is not permitted.&lt;&#x2F;p&gt;
&lt;p&gt;This is enforcement discretion, which is a weird idea if you stare at it. The statute says the exception ends when the shortage ends. The agency says it will not come after anyone for a while. It is last call at a bar: the bar is closed, but you can finish the drink in your hand, and the pitcher you ordered two minutes ago. You cannot order another.&lt;&#x2F;p&gt;
&lt;p&gt;The discretion was also partial. Law firm Foley &amp;amp; Lardner noted that the FDA’s policy said it “may still take action regarding violations of other statutory or regulatory requirements” for compounded semaglutide, such as a product being substandard or unsafe, “even within the grace period.” The grace covered the shortage problem. It did not cover every problem.&lt;&#x2F;p&gt;
&lt;p&gt;And here is the number I keep coming back to. The wind-down runs on beyond-use dates: what is already made can be used until that date. A 2025 survey of compounded GLP-1 products found 33 unique products, and only 18% of them provided beyond-use-date information. Eighteen percent of 33 is 5.94. So the official off-ramp for an industry serving millions of people was keyed to a date that about six products in that survey disclosed (presumably exactly six, since products are sort of hard to split). The others presumably had dates somewhere. Just not where the survey looked.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;so-is-compounded-semaglutide-legal-now-if-it-is-personalized&quot;&gt;So is compounded semaglutide legal now, if it is personalized?&lt;&#x2F;h2&gt;
&lt;p&gt;Now the sophisticated version, from the compounder’s side. The dumb version of continuing is to keep making the same copy and hope nobody notices. Something like that happened. Contrary Research reports that after the shortage ended, “some compounders and DTC platforms continued producing compounded GLP-1s, resulting in regulatory scrutiny and legal action from the FDA and Novo Nordisk.”&lt;&#x2F;p&gt;
&lt;p&gt;The sophisticated version uses the door that is still open: the 503A individual patient with a documented clinically significant difference. So the product becomes personalized. A different dose. A different salt (some compounders switched to semaglutide sodium or acetate, which another article here covers). An added ingredient, vitamins, etc.: in that 2025 survey, 48% of products contained combinations, including cyanocobalamin, glycine, niacinamide, docusate or ondansetron. You can almost hear the internal email: “Hey team, quick update, starting Monday our semaglutide is personalized, no action needed on your end.” (I made that email up, obviously.)&lt;&#x2F;p&gt;
&lt;p&gt;Then the vial arrives. It is semaglutide in a vial, at a monthly price that looks like the old one. The long road ends at the same place.&lt;&#x2F;p&gt;
&lt;p&gt;One reading is that this is what 503A is for: medicine is individual, some patients need something the commercial product does not offer, and a prescriber writing that down is doing the job. The other reading is that “clinically significant difference” has become a field on a form, and the difference is whatever fits in the field. The facts do not say which reading fits which pharmacy, and I feel like the answer is often both, in the same building.&lt;&#x2F;p&gt;
&lt;p&gt;The catch is that this stuff is exposed twice: to lawsuits from the companies that hold the drug approvals and to FDA enforcement, a dual legal exposure. As of August 5, 2025, Novo Nordisk had filed 132 complaints in federal courts across 40 states against companies whose marketing and practices around compounded semaglutide, in its view, put patients at risk. I would rather not think about what Novo’s lawyers have planned for complaint 133.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;where-the-patients-went&quot;&gt;Where the patients went&lt;&#x2F;h2&gt;
&lt;p&gt;The dumb version says patients switched back to brand. The facts here do not count where they actually went. Some presumably went to brand, some to personalized products, some to nothing. Not settled.&lt;&#x2F;p&gt;
&lt;p&gt;What is documented is that switching formats has costs of its own. The FDA put out a safety communication in July 2024 on dosing errors with compounded semaglutide, including patients who drew up several times the intended amount because the vial labeling differed from the pen format they had read about. In July 2025 it warned again, citing patients who mistakenly took five to 20 times the intended dose and needed hospitalization. (The dosing errors article on this site has the details.) Look, a pen and a vial are different objects. Moving millions of people between them, back and forth, with each move driven by a list, is going to produce some confusion, lol.&lt;&#x2F;p&gt;
&lt;p&gt;In February 2025 the FDA said there was enough semaglutide. There was. There was also, it turned out, plenty of the other kind, plus a legal reason to keep some of it around.&lt;&#x2F;p&gt;
&lt;p&gt;The shortage ended. The vials did not.&lt;&#x2F;p&gt;
</content>
        
    </entry>
    <entry xml:lang="en">
        <title>Compounded GLP-1s With Added B12 or Glycine: Medicine or Marketing?</title>
        <published>2026-11-01T00:00:00+00:00</published>
        <updated>2026-11-01T00:00:00+00:00</updated>
        
        <author>
          <name>
            
              Unknown
            
          </name>
        </author>
        
        <link rel="alternate" type="text/html" href="https://compoundglp.com/compounded-glp1-additives/"/>
        <id>https://compoundglp.com/compounded-glp1-additives/</id>
        
        <content type="html" xml:base="https://compoundglp.com/compounded-glp1-additives/">&lt;p&gt;I spent an evening this week reading a 2025 survey of compounded weight-loss injections, and the finding I keep coming back to is that about half of them are not only weight-loss injections. They have other stuff in them. The survey lists cyanocobalamin (vitamin B12), glycine, niacinamide, docusate and ondansetron, mixed in with the semaglutide or tirzepatide in the same product.&lt;&#x2F;p&gt;
&lt;p&gt;If you searched for semaglutide with b12, here is the plain answer. It is compounded semaglutide with cyanocobalamin added, made by a compounding pharmacy rather than by a drug manufacturer, and it is not an FDA-approved product. The survey that counted these combinations was published under the title “Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown,” and that title is about as far as the evidence goes. Nothing in the facts I have shows that the B12 makes the semaglutide work better or more safely. It is not settled. It is barely studied.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-semaglutide-with-b12-actually-is&quot;&gt;What semaglutide with B12 actually is&lt;&#x2F;h2&gt;
&lt;p&gt;A compounded drug is one a pharmacy mixes itself instead of buying it finished from a manufacturer. (The site has longer pieces on what compounders are and on the two kinds the law allows, so I will not redo them here.) Compounded semaglutide is semaglutide made this way. Compounded semaglutide with B12 is that, plus a vitamin.&lt;&#x2F;p&gt;
&lt;p&gt;The marketing word for these products tends to be “personalized,” which suggests a pharmacist looking at one particular patient and deciding that patient needs a little extra something. That is one possible description. The survey suggests another, which is that this is a catalog. There were 33 unique semaglutide and tirzepatide products in it, and the combinations recur across them. A personalized product that many people receive in the same form is sort of a product.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;why-the-law-makes-adding-a-vitamin-interesting&quot;&gt;Why the law makes adding a vitamin interesting&lt;&#x2F;h2&gt;
&lt;p&gt;Here is the rule. Compounders entered the GLP-1 market in 2022, when demand for semaglutide and tirzepatide outstripped supply and both drugs were placed on the FDA Drug Shortage List. That mattered because, as one source summarizing the law puts it, “Compounding a copy of an FDA-approved drug is ordinarily prohibited,” but the shortage exception in sections 503A and 503B allowed it while the drugs were on the list.&lt;&#x2F;p&gt;
&lt;p&gt;So the legal question is not really “is this drug good.” It is “is this a copy.” During a shortage, copies are fine. Without a shortage, copies are the problem.&lt;&#x2F;p&gt;
&lt;p&gt;The facts I have do not spell out what follows from that, so I will, labeled as my own inference: if the forbidden thing is a copy, then a thing that is not a copy might not be forbidden. The approved product is semaglutide. A vial of semaglutide plus a vitamin is, read very literally, a different preparation. Whether that literal reading actually holds up with regulators is not something these sources settle, and I would not pretend otherwise.&lt;&#x2F;p&gt;
&lt;p&gt;But you can see how the conversation might go. (This is invented.) A compliance consultant, on a call with a pharmacy, says: “Hey guys, it’s not a copy if it’s personalized. What are we personalizing it with?” Someone suggests B12. Everyone likes B12 (it has never once been the villain of a press release). B12 sounds healthy.&lt;&#x2F;p&gt;
&lt;p&gt;And then, in my invented version, it keeps going. If B12 makes it different, B12 plus glycine makes it more different. Add niacinamide for safety margin. Add docusate. Eventually the pharmacy is compounding a single vial containing a weight-loss drug, four supporting cast members, and a mild sense of legal distance, and the one thing it is definitely not is a copy of anything that has ever existed. This is made up. Mostly.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-the-evidence-says-about-the-additives&quot;&gt;What the evidence says about the additives&lt;&#x2F;h2&gt;
&lt;p&gt;The survey is the main evidence, and it is a count, not a trial. It does not test whether B12 does anything in these products. It just notices the B12 is there.&lt;&#x2F;p&gt;
&lt;p&gt;The number I cannot stop looking at is the 48%. That is the share of the 33 products that contained drug combinations. But 48% of 33 is 15.84 products, and you cannot have 0.84 of a product. Presumably the real figure is 16, which is 48.48% and rounds down nicely. I find this weirdly moving: someone sat with a spreadsheet of vitamin-laced weight-loss vials and did the honest arithmetic, and the rounding quietly hides a whole product. (I am aware that dwelling on the decimal places of a survey is not a normal way to spend an evening. It is, unfortunately, my job.)&lt;&#x2F;p&gt;
&lt;p&gt;The other number is worse. Only 18% of the products provided beyond-use-date information, meaning how long the preparation is good for once made. So the additives were often listed, and the expiration often was not. Priorities.&lt;&#x2F;p&gt;
&lt;p&gt;For safety, the broadest data comes from a study of the FDA Adverse Event Reporting System, by McCall and colleagues, covering 81,078 GLP-1 reports from 2018 to 2024, of which 707 involved compounded products. Compared with non-compounded versions, compounded products had a reporting odds ratio of 48.92 for preparation errors, 19.00 for contamination and 2.35 for hospitalization. Those confidence intervals are wide (the preparation-error one runs from 12.63 to 189.6), and these are reports, not proof of cause. Crucially for this article, the study looked at compounded GLP-1s as a group. It does not tell us whether the B12 versions were better, worse or the same. Nobody in these sources has measured that.&lt;&#x2F;p&gt;
&lt;p&gt;One oddity, briefly: compounded products showed lower odds of dosing errors, with an ROR of 0.24. The site’s piece on dosing errors handles that tangle, so I will leave it there.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-happened-after-the-shortage-ended&quot;&gt;What happened after the shortage ended&lt;&#x2F;h2&gt;
&lt;p&gt;The semaglutide shortage ended in February 2025. Some compounders and direct-to-consumer platforms kept making compounded GLP-1s anyway, which led to scrutiny and legal action. In September 2025 the FDA sent warning letters citing misleading direct-to-consumer advertising and marketing of compounded GLP-1s.&lt;&#x2F;p&gt;
&lt;p&gt;Novo Nordisk, which makes the branded semaglutide, went to court in volume. As of August 5, 2025, it had filed 132 complaints in federal courts across 40 states, describing the targets in a press release about “unsafe, non-FDA-approved compounded ‘semaglutide.’” (Note the scare quotes around the drug’s own name, which is a fairly pointed thing for a company to do to its own molecule.) That same day it filed 14 new suits against telehealth providers for allegedly steering patients toward compounded semaglutide. The lawsuits get their own article on this site.&lt;&#x2F;p&gt;
&lt;p&gt;The point for our purposes is timing. Once the shortage was over, the plain copy lost its legal cover. Whatever the additives were doing before, they mattered more after.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;three-ways-to-read-the-b12&quot;&gt;Three ways to read the B12&lt;&#x2F;h2&gt;
&lt;p&gt;There are, roughly, three ways to read a weight-loss injection that comes with a vitamin.&lt;&#x2F;p&gt;
&lt;p&gt;The first is that it is medicine. A pharmacist thinks some patients benefit from extra B12, and combining it saves a second shot. This is the reading the word “personalized” asks you to adopt, and it might be true for some prescribers. The trouble is just that the evidence for the combination, in the sources here, is close to zero. The survey’s own title says efficacy and safety are “largely unknown.”&lt;&#x2F;p&gt;
&lt;p&gt;The second is that it is marketing. Look, B12 sounds wholesome. A landing page offering a weight-loss shot “with B12” reads like a wellness product rather than a prescription drug made in a back room. The FDA’s September 2025 letters were specifically about misleading marketing of compounded GLP-1s, though the facts I have do not say any of them were about B12 in particular. It must simply be a happy coincidence that the ingredient chosen for its clinical value also photographs so well.&lt;&#x2F;p&gt;
&lt;p&gt;The third reading is the least comfortable one, and I feel like it is the one the law invites. The additive is not there for the patient, or for the advertisement. It is there for the statute. If copies are ordinarily prohibited, then the most useful property of B12 is that it makes the product not a copy, and “personalized” describes the vial’s relationship to section 503A rather than its relationship to anybody’s body. Then again, those readings can coexist: a pharmacist might sincerely believe in the B12 and also appreciate what it does for the paperwork, and from the outside I do not know how you would tell one motive from the other. The sources do not tell us either.&lt;&#x2F;p&gt;
&lt;p&gt;Which brings me back to that survey I read this week, and the half of the vials that had other things in them. I started out thinking the vitamins were the odd part. Now the vitamins seem like the most purposeful thing in the whole vial.&lt;&#x2F;p&gt;
&lt;p&gt;The vitamin is for the law.&lt;&#x2F;p&gt;
</content>
        
    </entry>
    <entry xml:lang="en">
        <title>The Dosing Errors FDA Keeps Seeing With Compounded GLP-1s</title>
        <published>2026-11-01T00:00:00+00:00</published>
        <updated>2026-11-01T00:00:00+00:00</updated>
        
        <author>
          <name>
            
              Unknown
            
          </name>
        </author>
        
        <link rel="alternate" type="text/html" href="https://compoundglp.com/compounded-glp1-dosing-errors/"/>
        <id>https://compoundglp.com/compounded-glp1-dosing-errors/</id>
        
        <content type="html" xml:base="https://compoundglp.com/compounded-glp1-dosing-errors/">&lt;p&gt;On July 29, 2024, the Food and Drug Administration put out a MedWatch alert about people injecting themselves with far too much compounded semaglutide. The alert went to patients, health professionals, pharmacies and endocrinology specialists, which is sort of everyone who touches the stuff. Its main finding was not that the drug in the vials was wrong. It was that people were drawing the wrong amount out of them.&lt;&#x2F;p&gt;
&lt;p&gt;So here is the plain answer on compounded semaglutide dosing errors. The FDA said most of the reports it received involved patients drawing more than the prescribed dose out of a multiple-dose vial, and that confusion between milligrams, milliliters and syringe “units” contributed. In the reported cases, patients took five to 20 times the intended dose, and some were hospitalized. Health care providers also miscalculated doses, so this was never only a patient problem.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;the-one-fda-sentence-that-explains-the-dosing-errors&quot;&gt;The one FDA sentence that explains the dosing errors&lt;&#x2F;h2&gt;
&lt;p&gt;The alert has one sentence that does most of the work, and it is worth reading the way a lawyer reads an indemnity clause. The FDA MedWatch alert says: “The majority of FDA-received dosing error reports described patients mistakenly drawing up more than the prescribed dose from a multiple-dose vial during self-administration of compounded semaglutide.”&lt;&#x2F;p&gt;
&lt;p&gt;Let’s take it clause by clause.&lt;&#x2F;p&gt;
&lt;p&gt;“The majority.” That means not all. Elsewhere the alert says errors came from patients measuring and injecting incorrect doses and also from health care providers miscalculating doses. So there is a minority of reports where the person holding the syringe did the math correctly and the math they were handed was wrong. That’s a weird category to have at all. (It is also the category that should worry the people writing the instructions.)&lt;&#x2F;p&gt;
&lt;p&gt;“Of FDA-received dosing error reports.” This is a statement about reports, not about patients. The FDA counts what people tell it. By April 30, 2025, it had received 520 adverse event reports related to compounded semaglutide. That is a count of forms. It is not a rate, because nobody in the facts here knows how many people were injecting the stuff.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-the-majority-of-reports-can-and-cannot-tell-you&quot;&gt;What “the majority of reports” can and cannot tell you&lt;&#x2F;h2&gt;
&lt;p&gt;The report problem gets stranger. A pharmacovigilance study using the FDA’s adverse event database from 2018 to 2024 found that compounded GLP-1 products had lower odds of dosing errors than non-compounded ones, with a reporting odds ratio of 0.24. A reporting odds ratio asks: among the reports filed about this product, how often is this problem mentioned, compared with reports about other products? So among reports about compounded GLP-1s, dosing errors showed up proportionally less often than among reports about the branded ones.&lt;&#x2F;p&gt;
&lt;p&gt;That sounds like the opposite of the FDA alert. It may not be. A pharmacist writing at PrecisionOptimize said most adverse events reported for compounded semaglutide appear to be dosing errors rather than formulation failures. Both claims can hold at once, because one is about the inside of a pile of reports and the other compares two piles. What the true error rate per patient is remains, on these facts, not settled.&lt;&#x2F;p&gt;
&lt;p&gt;Also, branded users make mistakes too. America’s Poison Centers says poison centers are most often contacted about accidental errors with the FDA-approved GLP-1 drugs, like doses taken too close together or higher than recommended. Poison centers reported a more than 15-fold rise in calls about injected weight-loss drugs since 2019, with many dosing errors more common with compounded multi-dose vials. The errors are ordinary. The size is not.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;why-a-multiple-dose-vial-turns-a-dose-into-a-math-problem&quot;&gt;Why a multiple-dose vial turns a dose into a math problem&lt;&#x2F;h2&gt;
&lt;p&gt;“Mistakenly drawing up more than the prescribed dose from a multiple-dose vial.” Here is the mechanism in plain words. You put a month or so of medicine in one little bottle, hand someone an empty syringe, and ask them to pull out the right sliver of it each week at the kitchen counter. The official name for this is a “multiple-dose vial” dispensed for “self-administration.”&lt;&#x2F;p&gt;
&lt;p&gt;The branded drug mostly comes in a prefilled pen, where you set a dose and the device does the measuring. A case series of calls to a poison control center put the difference flatly: “Vials of compounded semaglutide do not include the safety features provided by prefilled manufactured pens, making large overdoses (e.g., 10-fold dosing errors) possible.” A pen has a ceiling. A vial has a plunger and whatever is left in the bottle.&lt;&#x2F;p&gt;
&lt;p&gt;And the people holding the vials were often new to this. The FDA’s reports said many patients who got compounded vials lacked experience with self-injections. One account of the alert says some patients drew up several times the intended amount because the vial labeling differed from the pen format they had read about. They had studied for the wrong test. (This is the IKEA problem: the instructions show a different bookshelf than the one in the box, and you are holding a needle instead of an Allen key.)&lt;&#x2F;p&gt;
&lt;p&gt;“During self-administration.” At home. Alone.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;milligrams-milliliters-and-units-on-the-same-syringe&quot;&gt;Milligrams, milliliters and “units” on the same syringe&lt;&#x2F;h2&gt;
&lt;p&gt;The FDA identified confusion between milliliters, milligrams and “units” as a contributing factor. Between us, “units” is the word doing the most damage in this story. A milligram is an amount of drug. A milliliter is an amount of liquid. A “unit” is a tick mark on a syringe. Turning a prescription in one into a pull on the plunger in another requires knowing the concentration and doing a conversion, and every step is a chance to be off by a factor of ten.&lt;&#x2F;p&gt;
&lt;p&gt;The 2023 poison center case series is small, three patients, but two of the three gave themselves 10-fold dosing errors. One patient reported dosing in milliliters and units rather than milligrams. Look, a decimal point is a very small object.&lt;&#x2F;p&gt;
&lt;p&gt;A purely invented illustration of how it goes. The vial label speaks milligrams per milliliter. The prescription speaks milligrams. The syringe speaks units. A helpful person at the clinic calls and says, “Hey, so it’s ten on the syringe, not ten milligrams, and definitely not ten milliliters, ha.” The patient writes down “ten.” Next month the vial is a different concentration (made up, again), the syringe is a different size, and the patient is now a currency trader running a three-way conversion across milligrams, milliliters and units, with no Bloomberg terminal and a sharp object. By month three they are hedging. None of that is a real case. It is just the shape of the arithmetic.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-happened-to-the-people-who-got-the-math-wrong&quot;&gt;What happened to the people who got the math wrong&lt;&#x2F;h2&gt;
&lt;p&gt;The FDA said it received reports of adverse events, “some requiring hospitalization, that may be related to overdoses due to dosing errors.” The listed effects were nausea, vomiting, abdominal pain, fainting, headache, migraine, dehydration, acute pancreatitis and gallstones. The doses in those reports ran five to 20 times what was intended.&lt;&#x2F;p&gt;
&lt;p&gt;The FDA’s fix, among its recommendations, was that health care providers and compounders give patients the appropriate syringe size for the intended dose. If the syringe can only hold a small amount, you can only draw a small amount (physics remains an underrated regulator). It’s fine.&lt;&#x2F;p&gt;
&lt;p&gt;It is also a revealing fix. When the answer to a drug safety problem is “use a smaller cup,” the problem was never the chemistry.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;why-the-system-put-vials-in-kitchens-in-the-first-place&quot;&gt;Why the system put vials in kitchens in the first place&lt;&#x2F;h2&gt;
&lt;p&gt;Compounding a copy of an approved drug is ordinarily prohibited, but semaglutide and tirzepatide were on the FDA shortage list starting in 2022, and the shortage exception let compounders make them (other articles on this site cover how that list works). Compounders made what compounders make, which is vials. Telehealth brands sold subscriptions, and the line between a pharmacy, a prescriber and a marketing funnel got blurry: shared branding, shared customers, a shared checkout page, a shared interest in the refill.&lt;&#x2F;p&gt;
&lt;p&gt;Anyway, the shortage ended, and the FDA said compounded semaglutide and tirzepatide could not be distributed after May 22, 2025. On September 16, 2025, it sent more than 55 warning letters to online sellers. On February 6, 2026, it announced steps to restrict the active ingredients themselves. The 2024 alert about plungers and tick marks was, lol, one of the earlier and smaller items in a long file.&lt;&#x2F;p&gt;
&lt;p&gt;None of this required anything to be wrong with the molecule. The medicine came in a bottle, and the bottle came with homework.&lt;&#x2F;p&gt;
</content>
        
    </entry>
    <entry xml:lang="en">
        <title>The Compounded GLP-1 Lawsuits: Novo, Lilly and the Outsourcing Facilities</title>
        <published>2026-11-01T00:00:00+00:00</published>
        <updated>2026-11-01T00:00:00+00:00</updated>
        
        <author>
          <name>
            
              Unknown
            
          </name>
        </author>
        
        <link rel="alternate" type="text/html" href="https://compoundglp.com/compounded-glp1-lawsuits/"/>
        <id>https://compoundglp.com/compounded-glp1-lawsuits/</id>
        
        <content type="html" xml:base="https://compoundglp.com/compounded-glp1-lawsuits/">&lt;p&gt;The Outsourcing Facilities Association, a trade group for compounders that make drugs in large batches, sued the Food and Drug Administration on February 24, 2025, in Fort Worth, Texas, because the FDA had announced that there was enough semaglutide. Three days earlier the agency had issued a declaratory order saying the semaglutide injectable shortage was resolved. The trade group’s position, basically, was that the FDA had gotten the arithmetic wrong, and that the drug was still scarce.&lt;&#x2F;p&gt;
&lt;p&gt;If you typed “compounded semaglutide lawsuit” into a search engine, the plain answer is that there is no single lawsuit. There are several families of them. The first is OFA v. FDA, which argues that ending the shortage violated the Administrative Procedure Act; it was pending appeal before the Fifth Circuit as of May 2026, so its final result is not settled. The second is Novo Nordisk’s campaign against companies selling compounded semaglutide: 132 complaints in federal courts across 40 states and 44 permanent injunctions as of August 5, 2025, plus 14 newer suits under state corporate practice of medicine laws and a patent suit against Hims &amp;amp; Hers filed February 9, 2026.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;why-the-lawsuits-are-not-simply-about-patents&quot;&gt;Why the lawsuits are not simply about patents&lt;&#x2F;h2&gt;
&lt;p&gt;The sensible reaction here is that this is obviously a patent fight. Novo Nordisk invented semaglutide. Its semaglutide patents are not expected to expire until at least 2032, and Eli Lilly’s tirzepatide patents do not begin to expire until 2036. Somebody else is selling cheaper copies. A company with a patent sues people who copy the patented thing. That is the whole purpose of a patent.&lt;&#x2F;p&gt;
&lt;p&gt;To be fair, that intuition eventually came true. But for most of this story the fight was about something stranger: whether a shortage existed. Federal law lets compounders copy an approved drug in bulk when the drug is officially short. So the central legal question was never really “who owns this molecule?” It was “can the company that makes it make enough?”&lt;&#x2F;p&gt;
&lt;p&gt;That produces an inverted lawsuit. The compounders spent their legal energy arguing that the manufacturer could not keep up. The manufacturer spent its legal energy arguing that it could. Novo Nordisk filed a renewed motion to intervene in the case to support, in the words of the law firm publication Legal 500, “Novo Nordisk’s claim that it can meet high demand for its products.” It is unusual for a company to go to court to prove it has plenty of inventory. (Most companies prefer to prove this by selling it.)&lt;&#x2F;p&gt;
&lt;h2 id=&quot;how-the-shortage-rule-turned-into-a-lawsuit&quot;&gt;How the shortage rule turned into a lawsuit&lt;&#x2F;h2&gt;
&lt;p&gt;The rule works like this. Under Section 503B of the Food, Drug, and Cosmetic Act, outsourcing facilities may compound large volumes of drugs from bulk drug substances, without individual patient prescriptions, if the drug appears on the FDA’s drug shortage list “at the time of compounding, distribution, and dispensing,” as the law firm ArentFox Schiff puts it. Off the list, the exception disappears. After the shortage ended, 503B facilities could use bulk semaglutide only if it was on the shortage list or the approved bulk substances list, and it was on neither.&lt;&#x2F;p&gt;
&lt;p&gt;So the shortage list is not a passive record of what pharmacies have on hand. It is a switch (one with a surprising number of lawyers attached). When the FDA flipped it on February 21, 2025, it gave 503A state-licensed pharmacies until April 22, 2025, and 503B outsourcing facilities until May 22, 2025, to stop compounding under the shortage exception. That second window was 90 calendar days. Batches made before May 22 could still be sold until they expired, and the FDA said it could still act during the grace period against products that were substandard or unsafe.&lt;&#x2F;p&gt;
&lt;p&gt;Before issuing the order, the FDA collected information from Novo Nordisk and from patients, healthcare providers, pharmacy compounders, outsourcing facilities, telehealth companies and their associations. The OFA’s complaint is that this process, and the conclusion, violated the Administrative Procedure Act. This was its second try. The group had already brought a similar case over tirzepatide, with FarmaKeio Custom Compounding as a co-plaintiff, and Eli Lilly joined that case on New Year’s Day 2025. (Sources describe Lilly as a co-defendant in one place and as an approved “intervening party” in another. The distinction matters to lawyers and to almost no one else.)&lt;&#x2F;p&gt;
&lt;p&gt;The sources also disagree a little about the semaglutide case. One says it was assigned to Judge Reed O’Connor; another says Judge Mark Pittman accepted Novo’s renewed motion to intervene in case 4:25-cv-00174. Novo also filed an amicus brief supporting the FDA. A “renewed motion to intervene” is the dry legal phrase for showing up at someone else’s quarrel a second time because you simply could not stay out of it.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-novo-nordisk-s-compounded-semaglutide-suits-actually-claim&quot;&gt;What Novo Nordisk’s compounded semaglutide suits actually claim&lt;&#x2F;h2&gt;
&lt;p&gt;The other half of the litigation is Novo against sellers. As of August 5, 2025, the company had filed 132 complaints in federal courts across 40 states, targeting companies whose marketing and business practices, it said, put patient safety at risk.&lt;&#x2F;p&gt;
&lt;p&gt;Consider that number for a second. One hundred thirty-two complaints, 40 states. That works out to 3.3 lawsuits per state, which means somewhere a state got its fourth while another was still waiting on its third, like a very litigious franchise expansion. (I have spent an unreasonable part of this week dividing lawsuit counts by state counts, which is the sort of thing my job consists of.)&lt;&#x2F;p&gt;
&lt;p&gt;Courts had issued 44 permanent injunctions against defendants in those cases by the same date. That is a fair number of judges telling people to stop. Courts have also ordered defendants to give up illegally obtained profits. The facts available here describe these cases by what they targeted, marketing and business practices, rather than by every statute pleaded, so which counts in which complaint did the work is not something I can settle from them. Novo’s own framing also leans on supply quality, citing a Brookings Institution report that many compounded products use active ingredient imported from facilities in China lacking FDA oversight.&lt;&#x2F;p&gt;
&lt;p&gt;The patent suit came late. On February 9, 2026, Novo sued Hims &amp;amp; Hers for infringing U.S. Patent No. 8,129,343, alleging the company mass-compounded injectable versions of Wegovy made with “inauthentic API.” So the sensible reader’s patent theory did eventually arrive, roughly a year after the shortage ended. I assume a patent case is more appealing once the shortage defense is gone.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;the-state-law-cases-about-who-is-practicing-medicine&quot;&gt;The state-law cases about who is practicing medicine&lt;&#x2F;h2&gt;
&lt;p&gt;On August 5, 2025, Novo filed 14 new lawsuits against telehealth providers, alleging they violated state corporate practice of medicine laws by steering patients toward compounded semaglutide. These are, in some sense, the strangest suits of the bunch. They do not say the drug is copied. They say the wrong kind of entity is making the medical decision.&lt;&#x2F;p&gt;
&lt;p&gt;The theory, in Novo’s own description, is that corporations rather than doctors steered patient care toward compounded drugs “using sham claims of personalization.” The legal hook matters because compounding is supposed to be for a particular patient’s particular need. If a business sells one standard formula and calls it personalized, the personalization is doing legal work it may not be able to support. Here is an invented example of the problem, clearly made up: a marketing manager saying, “hey team, can we make the personalized dose come in three sizes, for scale.”&lt;&#x2F;p&gt;
&lt;p&gt;The facts here name California law specifically. They do not describe enforcement actions brought by state attorneys general or state pharmacy boards, so whether states themselves have sued compounders is not something these sources settle.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-the-courts-and-the-fda-have-decided-so-far&quot;&gt;What the courts and the FDA have decided so far&lt;&#x2F;h2&gt;
&lt;p&gt;The honest scoreboard is uneven. In the seller cases, Novo has a lot of results: permanent injunctions and disgorged profits. In OFA v. FDA, the cases over tirzepatide and semaglutide were pending appeal at the Fifth Circuit as of May 2026, which means the shortage fight is still, technically, a live question about something that ended in early 2025. It is like an instant replay review that runs long enough for the next season to start.&lt;&#x2F;p&gt;
&lt;p&gt;Meanwhile, the FDA has used its own tools. Its September 2025 warning letters to telehealth companies cited misleading direct-to-consumer advertising, resting on Section 502(bb), which bars false or misleading promotion of a compounded drug, and Section 502(a), which bars false or misleading labeling. And in May 2026 the agency proposed something that, per ArentFox Schiff, would, if finalized, “close the last remaining regulatory pathway” for large-scale 503B compounding of semaglutide, tirzepatide and liraglutide. That pathway is the 503B bulks list, which the OFA had nominated all three drugs for in 2024.&lt;&#x2F;p&gt;
&lt;p&gt;The point is that the trade group’s whole case rests on one empirical claim: that the manufacturer cannot supply everyone. I suppose that sets up an odd incentive. The single most useful thing a compounder could do for its appeal would be to go out and buy all the Wegovy.&lt;&#x2F;p&gt;
</content>
        
    </entry>
    <entry xml:lang="en">
        <title>What Independent Labs Found When They Tested Compounded Semaglutide</title>
        <published>2026-11-01T00:00:00+00:00</published>
        <updated>2026-11-01T00:00:00+00:00</updated>
        
        <author>
          <name>
            
              Unknown
            
          </name>
        </author>
        
        <link rel="alternate" type="text/html" href="https://compoundglp.com/compounded-semaglutide-potency-testing/"/>
        <id>https://compoundglp.com/compounded-semaglutide-potency-testing/</id>
        
        <content type="html" xml:base="https://compoundglp.com/compounded-semaglutide-potency-testing/">&lt;p&gt;Here is the odd fact at the center of compounded semaglutide: nobody is required to check what is in the vial before a patient injects it. A compounded drug is not an FDA-approved finished product, and compounded semaglutide has never been tested for safety, potency or effectiveness before use. So the published record of compounded semaglutide testing is mostly what happens afterward, when regulators inspect a facility or an independent lab buys some vials and measures them.&lt;&#x2F;p&gt;
&lt;p&gt;The plain answer is that the numbers are scattered, and most of the systematic ones are for the sister drug, tirzepatide. FDA warning letters have cited compounded semaglutide measured at 79.9% of its labeled potency. For tirzepatide, independent labs report that roughly 17% of compounded vials fall below 90% potency. Another set of tirzepatide samples measured between 101% and 132% of the labeled amount, and an aggregated database of 1,062 third-party tirzepatide tests shows an average purity of 99.75%. On endotoxin (the bacterial residue that sterile injectables are supposed to keep out) the published results gathered here give no figures at all, so that question is not settled.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-a-potency-test-actually-measures&quot;&gt;What a potency test actually measures&lt;&#x2F;h2&gt;
&lt;p&gt;It is worth being very literal about this. A lab takes a vial, figures out how much drug is actually in it, divides that by how much the label says is in it, and writes down the ratio. If the label says 10 and the lab finds 8, the vial gets an 80. This is called a potency assay.&lt;&#x2F;p&gt;
&lt;p&gt;A purity test asks a different question. It is not “how much drug is in here” but “of the stuff in here that looks like drug, how much is the right drug, as opposed to fragments, byproducts, etc.” A vial can be perfectly pure and badly underfilled, the way a glass of water can be entirely water and also mostly empty.&lt;&#x2F;p&gt;
&lt;p&gt;Let the record therefore reflect the following finding, which I state with the full gravity of the profession: 132 is greater than 100, 79.9 is less than 100, and both numbers are on labels that said 100. Potency is the Price Is Right, except that going over also loses. (I write about vials for a website, so this is roughly the level of math I get to do in public.)&lt;&#x2F;p&gt;
&lt;p&gt;There are, roughly, three ways to read the spread between those numbers. They get less comfortable as they go.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;the-first-reading-the-spread-is-mostly-noise&quot;&gt;The first reading: the spread is mostly noise&lt;&#x2F;h2&gt;
&lt;p&gt;The friendliest reading starts with the purity figure. If 1,062 tests across labs including ILS Laboratories, Accumark Labs, Krause Analytical, Freedom Diagnostics, Janoshik Labs and Kovera Labs average 99.75% purity, then at least the molecule being made is, mostly, the molecule. That is not nothing.&lt;&#x2F;p&gt;
&lt;p&gt;On this reading, an 80 here and a 132 there are the tails of a distribution, and every manufacturing process has tails. A pharmacist writing at PrecisionOptimize argued that most adverse events reported to FDA MedWatch for compounded semaglutide “appear to be dosing errors rather than formulation failures.” If the vials were routinely poisoning people, presumably the adverse event reports would say so (adverse event reports being, in fairness, the place where people say so).&lt;&#x2F;p&gt;
&lt;p&gt;That’s fine as far as it goes. The problem is that it goes about as far as the data, which is not far. An average purity number tells you nothing about the vial with the lowest purity, and it is a tirzepatide number being asked to vouch for semaglutide.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;the-second-reading-the-spread-is-the-product&quot;&gt;The second reading: the spread is the product&lt;&#x2F;h2&gt;
&lt;p&gt;The second reading is that variance is not a defect of this system but its natural output. An approved drug comes from a manufacturer that had to prove the thing works and keep proving it batch after batch. Compounded semaglutide never went through FDA bioequivalence testing, which even generics must pass before approval. Nothing upstream forces the numbers to cluster near 100.&lt;&#x2F;p&gt;
&lt;p&gt;Then there is the question of what goes into the vial. The FDA has reported that some compounders used different salt forms of semaglutide than the one in approved products, and using a salt instead of the base carries a greater potential for instability and variability. A Brookings Institution report noted that many compounded products rely on active ingredient imported from facilities in China that lack FDA oversight. When BioSpace covered the FDA’s findings about Empower Clinic Services, the agency’s finding was that Empower’s semaglutide and tirzepatide products were “essentially copies” of approved drugs, which is a separate legal problem but tells you how close to the original these things are trying to be.&lt;&#x2F;p&gt;
&lt;p&gt;Here is a scenario, entirely made up, to show where the incentives point. Suppose a telehealth brand learns that independent labs are publishing potency scores. It notices that nobody complains about a 112. So it overfills a little, and markets “verified 112% potency, more medicine per dollar.” A rival answers with 120. A third brand, charging somewhere in the $150 to $400 a month range that compounded semaglutide typically ran, launches a premium tier at 135. Eventually the label becomes a sort of floor, the tests become an advertising channel, and the one number nobody can find is the one printed on the vial.&lt;&#x2F;p&gt;
&lt;p&gt;That has not happened. I feel like it would not take much.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;the-third-reading-the-vial-is-not-the-main-problem&quot;&gt;The third reading: the vial is not the main problem&lt;&#x2F;h2&gt;
&lt;p&gt;The least comfortable reading is that the potency spread, which looks alarming, is the smaller of the two spreads. The bigger one happens after the vial leaves the pharmacy.&lt;&#x2F;p&gt;
&lt;p&gt;In a July 29, 2024 alert, the FDA said it had seen patients take five to 20 times the intended dose of compounded semaglutide. Most of those reports described people drawing up too much from a multiple-dose vial at home. The agency said confusion between milligrams, milliliters and syringe units may have contributed, and warned that compounded semaglutide comes in multiple concentrations. A 2023 case series from a poison control center found two of three patients had made tenfold errors, and pointed out that the vials “do not include the safety features provided by prefilled manufactured pens.” One patient got a vial and syringes with no pharmacist counseling; another measured in milliliters and units instead of milligrams.&lt;&#x2F;p&gt;
&lt;p&gt;Put the two spreads side by side. A vial at 132% potency is a third too strong. A dose drawn at ten times the intended volume is 900% too strong. If you multiply them, which is what actually happens inside a person, the lab’s finding is a rounding adjustment on the syringe’s finding. Reports of hospitalizations, acute pancreatitis and gallstones are what the FDA got back. By April 30, 2025, the agency had received 520 adverse event reports related to compounded semaglutide.&lt;&#x2F;p&gt;
&lt;p&gt;You can picture the conversation at the lab. “Hey, this batch came back at 132.” “Write it down.” “Should we flag it?” “Compared to what?” And that is the dumb part, structurally: the most careful measurement anyone takes of this product is precise to a decimal point, and it sits next to a patient measuring in syringe units that the label may not even use.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;why-the-semaglutide-data-is-so-thin&quot;&gt;Why the semaglutide data is so thin&lt;&#x2F;h2&gt;
&lt;p&gt;Part of the reason so many of these numbers are about tirzepatide is that semaglutide compounding was supposed to stop. The semaglutide shortage ended in February 2025, and the FDA set May 22, 2025 as the date after which distribution of compounded semaglutide and tirzepatide was prohibited. Some compounders and telehealth platforms kept going anyway. In a secret shopper study of 75 businesses, 92% were selling compounded semaglutide (the other 8% presumably had their reasons).&lt;&#x2F;p&gt;
&lt;p&gt;So the testing is, in a meaningful sense, testing of a product that is not supposed to exist in its current volume. The FDA has sent warning letters to telehealth sellers in rounds dated September 2025, February 2026 and June 2026. Novo Nordisk had filed 132 complaints in federal courts across 40 states by August 5, 2025, with 44 permanent injunctions issued, and in February 2026 it sued Hims &amp;amp; Hers, alleging its compounded semaglutide was made with inauthentic active ingredient. I would rather not think about what Novo’s lawyers have planned for complaint 133.&lt;&#x2F;p&gt;
&lt;p&gt;The result, I guess, is that the institutions with the most reason to measure compounded semaglutide are regulators building enforcement files and a drugmaker building lawsuits. The institution with the most direct, unplanned measurement of what a real dose of it does is the poison control center.&lt;&#x2F;p&gt;
</content>
        
    </entry>
    <entry xml:lang="en">
        <title>Compounded Semaglutide: What You Are Actually Getting</title>
        <published>2026-11-01T00:00:00+00:00</published>
        <updated>2026-11-01T00:00:00+00:00</updated>
        
        <author>
          <name>
            
              Unknown
            
          </name>
        </author>
        
        <link rel="alternate" type="text/html" href="https://compoundglp.com/compounded-semaglutide/"/>
        <id>https://compoundglp.com/compounded-semaglutide/</id>
        
        <content type="html" xml:base="https://compoundglp.com/compounded-semaglutide/">&lt;p&gt;In 2023 a poison control center published a short case series about people who had injected the wrong amount of a weight-loss drug. One detail stands out. A patient got the drug from a compounding pharmacy as a vial and some syringes for self-administration, with no pharmacist counseling on how to actually administer it. That patient had compounded semaglutide: the active ingredient in Novo Nordisk’s Ozempic and Wegovy, made by someone other than Novo Nordisk, usually sold in a multiple-dose vial rather than a prefilled pen, and never approved by the FDA as a finished drug product.&lt;&#x2F;p&gt;
&lt;p&gt;So the plain answer to “what is it” is roughly this. It is the same molecule, more or less (the “more or less” is doing some work, and we will get to it), from a different source, with much less testing. It has never undergone FDA bioequivalence testing. It has no randomized trial data behind it. It typically cost patients between $150 and $400 a month. Its legal footing, as best you can read it off the calendar, was a drug shortage: the semaglutide shortage ended in February 2025, the deadline for 503B outsourcing facilities to stop making new batches was May 22, 2025, and the FDA prohibited distribution after that date. Some businesses kept selling anyway.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;the-dumb-version-of-compounded-semaglutide&quot;&gt;The dumb version of compounded semaglutide&lt;&#x2F;h2&gt;
&lt;p&gt;Here is a deliberately dumb version, made up for illustration. A guy buys semaglutide powder from a factory overseas. He dissolves it in something sterile-ish, fills some vials, and ships them to strangers along with a bag of syringes. The strangers work out how much to inject by reading about the branded pen online and doing some arithmetic.&lt;&#x2F;p&gt;
&lt;p&gt;Obviously this is not allowed.&lt;&#x2F;p&gt;
&lt;p&gt;It is worth stating the dumb version anyway, because it isolates the three things that make the product what it is. The ingredient comes from somewhere other than the company that ran the trials. Nobody checks the finished vial the way a regulator checks an approved drug. And the dose is assembled at the end, by the patient, out of a vial, a syringe and some units.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;the-sophisticated-version-with-licenses-and-doctors&quot;&gt;The sophisticated version, with licenses and doctors&lt;&#x2F;h2&gt;
&lt;p&gt;The real version is much more elaborate. There is a licensed compounding pharmacy (either a 503A pharmacy or a 503B outsourcing facility, a distinction with its own article on this site). There is a prescriber. There is, often, a telehealth brand with a nice website, a subscription and a monthly price well below the branded drug. The telehealth companies and the compounders hooked up in a big way, and for a while it was a very satisfying arrangement for everyone involved.&lt;&#x2F;p&gt;
&lt;p&gt;And there was a reason it was allowed: the branded drug was in shortage, and the timing of what happened when the shortage ended tells you the shortage was carrying the legal weight. (The exact mechanics of the shortage list are another article here; the dates above are the part that matters for this one.) I feel like everyone in the business understood this, which is why the end of the shortage produced so much creative thinking. “Hey, the shortage is over,” you can imagine a growth lead saying in a meeting, “but is it over over?”&lt;&#x2F;p&gt;
&lt;p&gt;Now walk the sophisticated version to its end. Where does the licensed pharmacy get the active ingredient? Who tests the finished vial before it ships? What does the patient hold at the end?&lt;&#x2F;p&gt;
&lt;p&gt;The same three answers.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;where-the-active-ingredient-comes-from&quot;&gt;Where the active ingredient comes from&lt;&#x2F;h2&gt;
&lt;p&gt;Novo Nordisk does not sell its semaglutide to compounders, so compounders buy active pharmaceutical ingredient, or API, from other manufacturers. Novo, in a statement about its lawsuits, pointed to a Brookings Institution report that many compounded products rely on synthetic API imported from facilities in China that lack FDA oversight or quality controls. That’s Novo’s framing, and Novo presumably has its own interests here, but the underlying point about sourcing is not really in dispute.&lt;&#x2F;p&gt;
&lt;p&gt;There is also the “more or less” from earlier. Some compounded products used semaglutide salt rather than semaglutide base, and the salt version has a greater potential for drug instability and variability, which can raise the risk of side effects or of the drug just not working. (The salt forms get their own article; here it is enough to know that “semaglutide” on a label is a less specific word than it looks.)&lt;&#x2F;p&gt;
&lt;p&gt;The other odd thing about sourcing is that being a copy is sort of the point. When the FDA went after Empower Clinic Services, BioSpace reported, the agency found that Empower’s compounded tirzepatide and semaglutide products appeared to be copies of FDA-approved products. Patients wanted the approved drug, cheaper. A product that was not a copy would not have sold. A product that was a copy was, once the shortage ended, the problem.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-testing-it-gets-before-it-reaches-a-patient&quot;&gt;What testing it gets before it reaches a patient&lt;&#x2F;h2&gt;
&lt;p&gt;An approved drug goes through trials, review, manufacturing inspection, etc. A generic has to prove it is equivalent to the brand before approval. The compounded product does none of that. It is not tested for safety, potency or effectiveness before use, and it has not been through bioequivalence testing at all.&lt;&#x2F;p&gt;
&lt;p&gt;What testing exists happens at the pharmacy level, and the quality of it varies. One data point: FDA warning letters have cited subpotent semaglutide measured at 79.9% of its labeled potency. That’s a product that says one amount on the label and contains about four-fifths of it, which is the kind of stuff a finished-product review is designed to catch.&lt;&#x2F;p&gt;
&lt;p&gt;Whether any given compounder’s testing is good is not settled by any single number, and judging that is a whole separate article on this site.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;why-the-vial-matters-more-than-the-molecule&quot;&gt;Why the vial matters more than the molecule&lt;&#x2F;h2&gt;
&lt;p&gt;On July 29, 2024, the FDA issued a MedWatch alert about dosing errors with compounded injectable semaglutide. Patients had given themselves five to 20 times the intended dose. By April 30, 2025, the FDA had received 520 adverse event reports tied to compounded semaglutide, and the reported effects included nausea, vomiting, abdominal pain, fainting, headache, migraine, dehydration, acute pancreatitis and gallstones, some requiring hospitalization.&lt;&#x2F;p&gt;
&lt;p&gt;The mechanism is not mysterious. The patient was supposed to pull the plunger back a little, and pulled it back a lot. The FDA’s MedWatch alert calls this “mistakenly drawing up more than the prescribed dose from a multiple-dose vial,” and it was the majority of the reports.&lt;&#x2F;p&gt;
&lt;p&gt;Let us set out the governing principle with the rigor it deserves. A multiple-dose vial is, by definition and by design, a container holding more than one dose. It follows, as a matter of plain construction, that a person drawing from it is physically able to draw more than one dose. The branded pen does not have this property. The poison control case series put it this way: vials “do not include the safety features provided by prefilled manufactured pens, making large overdoses (e.g., 10-fold dosing errors) possible.” Two of the three patients in that series had 10-fold errors.&lt;&#x2F;p&gt;
&lt;p&gt;Then add units. The FDA said confusion among milligrams, milliliters and syringe “units” contributed to the errors, and one patient in the case series dosed in milliliters and units instead of milligrams. It is also not just patients: some errors came from health care providers miscalculating doses, and the FDA warned that different compounders may sell different concentrations, so the same number of units out of two different vials can be two different doses.&lt;&#x2F;p&gt;
&lt;p&gt;Imagine (this is invented) a baking show where every contestant gets a recipe in cups, every pantry stocks flour in a different density, and the judges dock points for collapsed cakes. Somebody’s cake is going to collapse, and it won’t be because they can’t bake. A pharmacist writing at PrecisionOptimize made roughly this observation in clinical terms: most adverse events reported to MedWatch for compounded semaglutide appear to be dosing errors rather than formulation failures. The molecule was fine-ish. The packaging was the risk.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-happened-after-the-shortage-ended&quot;&gt;What happened after the shortage ended&lt;&#x2F;h2&gt;
&lt;p&gt;Contrary Research summarized the aftermath flatly: after the shortage ended, some compounders and direct-to-consumer platforms kept producing, “resulting in regulatory scrutiny and legal action from the FDA and Novo Nordisk.” By August 5, 2025, Novo had filed 132 complaints in federal courts across 40 states, and courts had issued 44 permanent injunctions. The FDA sent warning letters to telehealth companies in three rounds, in September 2025, February 2026 and June 2026. A secret shopper study of 75 businesses found that 92% sold compounded semaglutide.&lt;&#x2F;p&gt;
&lt;p&gt;The most visible case: on February 5, 2026, Hims &amp;amp; Hers advertised the commercial launch of a compounded semaglutide tablet, and on February 9, 2026, Novo sued it for infringing US Patent No. 8,129,343, alleging it mass-compounded injectable versions of Wegovy made with inauthentic API. How that ends is not settled.&lt;&#x2F;p&gt;
&lt;p&gt;Now take the sophisticated version and keep making it more responsible, which is presumably what regulators would like. (Made-up scenario, to be clear.) A compounder verifies its API back to an FDA-inspected plant. Then it tests every batch for potency. Then, worried about vials, it ships in prefilled pens with a dial so nobody counts units. Then it runs a randomized trial, and a bioequivalence study, and submits it all to the FDA for review, and builds a factory big enough that there is never a shortage again. That’s fine. It is also a description of Novo Nordisk.&lt;&#x2F;p&gt;
&lt;p&gt;The most sophisticated compounded semaglutide possible is Wegovy at full price.&lt;&#x2F;p&gt;
</content>
        
    </entry>
    <entry xml:lang="en">
        <title>Why Compounded Tirzepatide Costs What It Costs</title>
        <published>2026-11-01T00:00:00+00:00</published>
        <updated>2026-11-01T00:00:00+00:00</updated>
        
        <author>
          <name>
            
              Unknown
            
          </name>
        </author>
        
        <link rel="alternate" type="text/html" href="https://compoundglp.com/compounded-tirzepatide-cost/"/>
        <id>https://compoundglp.com/compounded-tirzepatide-cost/</id>
        
        <content type="html" xml:base="https://compoundglp.com/compounded-tirzepatide-cost/">&lt;p&gt;If you are a pharmacist, and a doctor calls about one patient who can’t use the commercial version of a drug, the job is fairly simple. You get the ingredient, mix it, put it in a vial and hand it over, and you charge for the powder, your time, the vial and a bit of profit. The price of that vial is basically the price of making one thing by hand for one person. It is a handmade price.&lt;&#x2F;p&gt;
&lt;p&gt;Compounded tirzepatide is that idea pushed a long way down the road, and the price is less tidy than you would hope. None of the sources I have puts a single number on compounded tirzepatide cost specifically. The closest figure is for its cousin: a 2026 legal explainer says compounded semaglutide “typically cost patients between $150 and $400 per month.” Brand-name versions of both drugs run $800 to $1,500 a month without insurance, and as of March 2026 Pharmacy Times reported that TrumpRx listed tirzepatide injections at $299 to $449 a month, against $1,087 for branded alternatives. So the compounded product lives somewhere in the low hundreds, and the brand has been walking down the street toward it.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;why-the-compounded-tirzepatide-price-starts-with-a-legal-exception&quot;&gt;Why the compounded tirzepatide price starts with a legal exception&lt;&#x2F;h2&gt;
&lt;p&gt;The legal hook for compounding tirzepatide at all is narrow. Rx.com’s potency guide says it “can only be prepared when a prescriber attests that the commercial drug does not meet a patient’s medical need, often due to cost or supply issues.” Notice the word “cost” sitting in there. That’s fine, as far as it goes. A drug that costs $1,087 a month does fail to meet some people’s needs, in the sense that they cannot pay for it.&lt;&#x2F;p&gt;
&lt;p&gt;For the bigger outsourcing facilities, though, the FDA reads it differently. According to the law firm ArentFox Schiff, when the FDA assesses “clinical need” for its 503B bulks list, it does not consider “the cost of the compounded product compared with an FDA-approved drug.” Flatly: being cheaper than the real thing is not, to the FDA, a medical reason. So price is the entire reason the market exists, and price is the one thing the official test declines to look at. (The 503A versus 503B plumbing gets its own article on this site.)&lt;&#x2F;p&gt;
&lt;h2 id=&quot;step-two-buy-the-powder-by-the-bag&quot;&gt;Step two: buy the powder by the bag&lt;&#x2F;h2&gt;
&lt;p&gt;Now escalate. Suppose (this is a hypothetical I am inventing) the pharmacist gets that call a hundred times a week. She stops ordering ingredient for one patient and starts buying bulk active pharmaceutical ingredient, the API, which is the actual drug as a powder. She stops mixing single doses and fills multi-dose vials, which for compounded tirzepatide range from 5 mg to 50 mg, diluted with bacteriostatic water. Each vial is weeks of product made in one go. The per-dose cost falls. That’s the trick.&lt;&#x2F;p&gt;
&lt;p&gt;What does the powder cost? I don’t know, and I mean that literally: none of my sources gives a per-gram price for tirzepatide API, and any number I offered would be invented. What they do describe is where powder like this comes from, which is presumably related to its price. A Brookings Institution report, cited by Novo Nordisk, said many compounded semaglutide products rely on API imported from facilities in China “that lack FDA oversight or quality controls.” Novo also alleged that Hims &amp;amp; Hers made injectable semaglutide with inauthentic API. And on February 6, 2026, the FDA announced steps to restrict GLP-1 APIs used in non-approved compounded products. Cheap inputs have reasons.&lt;&#x2F;p&gt;
&lt;p&gt;Bulk work has its own arithmetic. Rx.com notes that a 5 mg weighing error on a 50 mg batch produces a 10% potency swing, and that potency loss most often happens when pharmacies reconstitute bulk powder in unvalidated clean rooms. Independent labs report roughly 17% of compounded tirzepatide vials falling below 90% potency, and some lots contain as little as 72% of the stated dose. I feel like this is the line item nobody prints on the invoice. A vial that is 72% as strong is, in a dumb literal sense, a 28% discount that nobody asked for. (Accountants call this “shrink” when it happens to inventory; it is less charming when it happens inside a syringe.)&lt;&#x2F;p&gt;
&lt;h2 id=&quot;step-three-the-telehealth-markup-and-why-nobody-can-measure-it&quot;&gt;Step three: the telehealth markup, and why nobody can measure it&lt;&#x2F;h2&gt;
&lt;p&gt;Escalate again. The pharmacist does not want to run ads, host video visits or answer customer email at 11 p.m. A telehealth startup does. It signs patients up, routes them to a prescriber, sends the prescription to a pharmacy, and ships a vial in a box with its own logo. ArentFox Schiff describes the compounded GLP-1 market as “fueled by telehealth startups and cash-pay obesity clinics.” It is a ghost kitchen: the restaurant on the delivery app has a name, a logo and nice photos, and the food comes out of a building you will never see.&lt;&#x2F;p&gt;
&lt;p&gt;The pharmacy, in this arrangement, is discreet. FDA warning letters repeatedly flagged telehealth companies branding products under their own names without disclosing which pharmacy compounded the drug. That is a fine arrangement for a brand and an awkward one for anyone trying to figure out who made the thing (or, more relevant here, who is keeping which slice of the monthly fee).&lt;&#x2F;p&gt;
&lt;p&gt;Because that is where the markup lives, and I can’t tell you how big it is. The sources do not split a monthly price into the pharmacy’s share and the platform’s share. Presumably the platform’s slice covers the prescriber, the advertising, the customer service, the shipping, the subscription software, profit, etc. Pharmacy margin is equally unpublished. (I write about compounding pharmacies for a living, and a surprising amount of the job is reporting which numbers do not exist.)&lt;&#x2F;p&gt;
&lt;p&gt;What does exist is a stack of letters. The FDA sent warning letters to telehealth sellers of compounded semaglutide and tirzepatide in rounds dated September 2025, February 2026 and June 2026, including 30 announced on March 3, 2026 and a third wave on June 8, 2026. FDA guidance says it is misbranding to describe a compounded product as a “generic version” of an approved drug or “the same as” one. The legal basis is Section 502(bb) of the Food, Drug, and Cosmetic Act, which, translated flatly, says you cannot lie in ads specifically about compounded drugs.&lt;&#x2F;p&gt;
&lt;p&gt;I am imagining the marketing meeting here, to be clear. “Hey team, can we call it the generic?” “No.” “Can we say it’s the same?” “Also no.” “Okay, what can we say about the ingredient?” Long pause.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;the-endpoint-the-brand-shows-up-at-the-compounder-s-price&quot;&gt;The endpoint: the brand shows up at the compounder’s price&lt;&#x2F;h2&gt;
&lt;p&gt;Push the hypothetical to its end. The platform grows until it is, functionally, the cheap generic of a drug that has no generic. It has a logo, a subscription, a price card and a celebrity ad, and somewhere behind it a pharmacy with a bag of imported powder. Then the manufacturer, rather than letting this continue, opens its own cash window and charges roughly the same price. Now the knockoff is competing on price with the original, at the original’s new price, while carrying all of the knockoff’s risks. Its one advantage was cost. That advantage is gone or whatever.&lt;&#x2F;p&gt;
&lt;p&gt;That sounds absurd, and the real world is most of the way there. TrumpRx’s tirzepatide range of $299 to $449 overlaps the $150 to $400 range reported for compounded semaglutide. Novo Nordisk announced on February 24, 2026 that it would cut the list price of Wegovy, Ozempic and Rybelsus to $675 a month across all doses, effective January 1, 2027. Meanwhile the shortage that made mass compounding possible is over (another article on this site covers how it ended), and the FDA, in deciding it had ended, reviewed Eli Lilly’s expanded manufacturing capacity.&lt;&#x2F;p&gt;
&lt;p&gt;The obvious reading, I guess, is that compounders discovered the price. They showed manufacturers that a huge number of people would pay a few hundred dollars a month, cash, for this drug, and the manufacturers then took the business back. Read the dates a second way, though, and the compounders discovered nothing: capacity expanded, the shortage ended, and the brand prices came down on their own schedule, with the compounders as a temporary bridge that happened to have good ads. The sources do not settle which story is the real one.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;back-to-the-pharmacist-with-one-vial&quot;&gt;Back to the pharmacist with one vial&lt;&#x2F;h2&gt;
&lt;p&gt;So return to the pharmacist and her one vial for one patient. It is still a vial. It now holds up to 50 mg, carries an app’s logo instead of her name, starts as powder from a facility nobody inspected, and gets priced against a government website listing the brand at $299. Somewhere in that chain, someone had to decide what to say about the ingredient.&lt;&#x2F;p&gt;
&lt;p&gt;Altru Telehealth’s website claimed its compounded semaglutide and tirzepatide contained an “FDA approved active ingredient.”&lt;&#x2F;p&gt;
</content>
        
    </entry>
    <entry xml:lang="en">
        <title>Compounded Tirzepatide and the Shortage That Ended</title>
        <published>2026-11-01T00:00:00+00:00</published>
        <updated>2026-11-01T00:00:00+00:00</updated>
        
        <author>
          <name>
            
              Unknown
            
          </name>
        </author>
        
        <link rel="alternate" type="text/html" href="https://compoundglp.com/compounded-tirzepatide/"/>
        <id>https://compoundglp.com/compounded-tirzepatide/</id>
        
        <content type="html" xml:base="https://compoundglp.com/compounded-tirzepatide/">&lt;p&gt;The way a compounded copy of a famous drug gets to exist, legally, is that the real drug shows up on a list. Compounding a copy of an FDA-approved drug is ordinarily prohibited, but federal law has a shortage exception: while a drug sits on the FDA’s drug shortage list, state-licensed 503A pharmacies and registered 503B outsourcing facilities may make it. Tirzepatide, Eli Lilly’s injectable GLP-1, went on that list in 2022, when demand outstripped supply. A lot of people started making it.&lt;&#x2F;p&gt;
&lt;p&gt;Then it came off. The FDA declared the tirzepatide shortage resolved on October 2, 2024, reaffirmed that on December 19, 2024 after a court remand, and gave compounders grace periods that ended February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B facilities. The industry’s trade group sued and lost, and in September 2026 it was reported that the Fifth Circuit had upheld the FDA. So the plain answer on where compounded tirzepatide stands is that the exception that made the mass-market version legal is gone, and a federal appeals court has said the FDA was allowed to take it away.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;how-a-shortage-list-became-a-business-license&quot;&gt;How a shortage list became a business license&lt;&#x2F;h2&gt;
&lt;p&gt;The exception is narrow on paper. As the law firm ArentFox Schiff summarizes Section 503B, an outsourcing facility may compound large volumes from bulk drug substances, without individual prescriptions, if the drug appears on the shortage list “at the time of compounding, distribution, and dispensing.” (That is three separate moments, each of which has to land on the right side of a list.) It is not a general right to compound popular medicines. It is a permission that lasts while a web page says a particular thing.&lt;&#x2F;p&gt;
&lt;p&gt;And yet the GLP-1 compounding market grew into a multibillion-dollar sub-industry on that permission. Which makes sense, I suppose. If you tell an industry it may sell a drug millions of people want for as long as a government list calls the drug scarce, you have basically created a business whose central asset is a line of text.&lt;&#x2F;p&gt;
&lt;p&gt;Here is an invented case, and it is purely invented. A facility compounds a batch at 4 p.m. while tirzepatide is listed. The list updates overnight. The batch ships at 9 a.m. It was legal when made and is not legal when shipped, so in some sense it became illegal in a box on a loading dock. If the list flickered on and off every hour, the optimal business would be a lab that compounds only on the hour, a courier who drives only on the half hour, and a lawyer who sleeps never.&lt;&#x2F;p&gt;
&lt;p&gt;The grace periods exist partly because of this. Real operations do not switch off when a page refreshes (no matter how many times a compliance officer hits refresh).&lt;&#x2F;p&gt;
&lt;h2 id=&quot;why-the-tirzepatide-shortage-ended-twice&quot;&gt;Why the tirzepatide shortage ended twice&lt;&#x2F;h2&gt;
&lt;p&gt;The shortage ended on October 2, 2024. Then it ended again.&lt;&#x2F;p&gt;
&lt;p&gt;Between those dates there was a court remand (the sources here do not spell out its details), the FDA looked again, and on December 19, 2024 tirzepatide injection products were removed from the list “by declaratory order.” A declaratory order, in this case, is the FDA formally writing down that it still meant what it said in October. It is a little Groundhog Day, except the weather never changed.&lt;&#x2F;p&gt;
&lt;p&gt;What the FDA looked at was Lilly’s expanded manufacturing capacity, alongside information from manufacturers, compounders, patients, healthcare professionals, telehealth companies and others. I assume the conversation at a lot of compounders that fall went something like: “Is it still short?” “Lilly says no.” “Is Lilly the one we’re asking?”&lt;&#x2F;p&gt;
&lt;p&gt;That last question became the lawsuit.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-the-compounders-argued-in-court&quot;&gt;What the compounders argued in court&lt;&#x2F;h2&gt;
&lt;p&gt;The Outsourcing Facilities Association, or OFA, filed federal lawsuits challenging the FDA’s determinations that both the tirzepatide and semaglutide shortages were over. (The semaglutide story has its own article on this site, and I will leave it there.) This is the part where people like me, who read administrative procedure filings voluntarily and then wonder why the dinner party went quiet, get excited.&lt;&#x2F;p&gt;
&lt;p&gt;OFA’s first argument was about procedure. It said the shortage resolution was really rulemaking, not adjudication, because it “declared the law going forward” for the whole compounding industry. Rules under the Administrative Procedure Act generally need notice and comment. The FDA had not done notice and comment. So, OFA argued, the decision was invalid.&lt;&#x2F;p&gt;
&lt;p&gt;The second argument was about facts. OFA said the original removal was based “entirely on Lilly’s representation of the situation, rather than on reality,” with “scant explanation,” and that the FDA doubled down even after seeing evidence of surging demand, regional and national scarcity, and delays filling prescriptions. Is a shortage a fact about pharmacies, or a rule about compounders? OFA’s case needed it to be both.&lt;&#x2F;p&gt;
&lt;p&gt;On March 5, 2025, Judge Mark Pittman entered a sealed opinion denying OFA’s motion for a preliminary injunction. Part of the evidentiary fight, per later reporting on the appeal, involved access-problem data collected through a Hims &amp;amp; Hers website (a telehealth company, which I am sure approached the question of whether compounding should continue in a spirit of pure scholarship). The FDA discounted those submissions because they did not reliably show when the problem happened, where the user was, why they could not get the drug, or whether one person had filed several times. That is a fairly complete list of things a survey is for.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;how-the-fifth-circuit-settled-it&quot;&gt;How the Fifth Circuit settled it&lt;&#x2F;h2&gt;
&lt;p&gt;The appeal was pending before the Fifth Circuit as of May 2026 (appellate courts keep their own calendar, and it is not a fast one). In September 2026 it was reported that the court upheld the FDA’s determinations removing both semaglutide and tirzepatide from the shortage list. The notice-and-comment argument did not carry the day, or whatever the precise doctrinal phrasing turns out to be once everyone has read the opinion closely.&lt;&#x2F;p&gt;
&lt;p&gt;The point is that the shortage being over is now a settled legal fact. Whether it is a settled fact about the world is a slightly different question.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;three-ways-to-read-the-compounded-tirzepatide-fight&quot;&gt;Three ways to read the compounded tirzepatide fight&lt;&#x2F;h2&gt;
&lt;p&gt;There are, roughly, three ways to read this.&lt;&#x2F;p&gt;
&lt;p&gt;The first is that the system worked. A real supply problem appeared in 2022, compounders filled the gap under an exception built for exactly that, Lilly built capacity, the FDA checked, the exception closed, and courts confirmed it. Bridges are supposed to end.&lt;&#x2F;p&gt;
&lt;p&gt;The second is OFA’s reading: the FDA leaned on the one party with the most to gain from the list closing, and waved off messier evidence from patients and pharmacies. You and I both know that “the manufacturer can now make enough” and “everyone who wants it can afford what it costs” are different sentences. A shortage list only has room for one of them. The courts said the FDA could pick, which is not quite the same as saying it picked right.&lt;&#x2F;p&gt;
&lt;p&gt;The third is the least comfortable. The shortage list was never built to hold up a multibillion-dollar industry, and the demand it was holding up did not leave when the listing did. A secret shopper study identified 75 businesses still selling compounded GLP-1s, and 86.7% of them sold compounded tirzepatide. The FDA sent warning letters to telehealth sellers in three rounds, in September 2025, February 2026 and June 2026. It found that one compounder, Empower Clinic Services, made tirzepatide and semaglutide products the agency called essentially copies of the approved ones, which is the precise thing the ordinary rule forbids. Compounders now face lawsuits from drug makers and enforcement from the FDA at once, sort of thing.&lt;&#x2F;p&gt;
&lt;p&gt;And underneath it all, compounded tirzepatide has never been reviewed by the FDA for safety, effectiveness, purity or stability, even from a fully licensed pharmacy. The trial numbers people cite, like SURMOUNT-1, come from Lilly’s own injectable. That was true when the drug was listed, too. The list never measured the product. It measured the scarcity.&lt;&#x2F;p&gt;
&lt;p&gt;I don’t know how this ends for the remaining sellers. It is not settled. What is settled is the thing that started it: for a few years a whole industry ran on a line on a list, and the line is gone.&lt;&#x2F;p&gt;
&lt;p&gt;The customers were never on the list.&lt;&#x2F;p&gt;
</content>
        
    </entry>
    <entry xml:lang="en">
        <title>Compounded vs Brand Semaglutide: The Differences That Matter</title>
        <published>2026-11-01T00:00:00+00:00</published>
        <updated>2026-11-01T00:00:00+00:00</updated>
        
        <author>
          <name>
            
              Unknown
            
          </name>
        </author>
        
        <link rel="alternate" type="text/html" href="https://compoundglp.com/compounded-vs-brand-semaglutide/"/>
        <id>https://compoundglp.com/compounded-vs-brand-semaglutide/</id>
        
        <content type="html" xml:base="https://compoundglp.com/compounded-vs-brand-semaglutide/">&lt;p&gt;Here is a sentence from federal pharmacy law that has been asked to carry most of a weight-loss industry on its back. Under 21 U.S.C. § 353a, a compounded drug does not count as “essentially a copy of a commercially available drug product” if there is a change, made for an identified individual patient, that produces a significant difference between the compounded drug and the approved one, with that difference “as determined by the prescribing practitioner.” Most of what people mean by compounded ozempic lives inside that sentence, or is trying to.&lt;&#x2F;p&gt;
&lt;p&gt;So, plainly: compounded semaglutide is not Ozempic. Wegovy and Ozempic are the only FDA-approved semaglutide injection products. Compounded semaglutide is not FDA-approved as a finished drug product, and the FDA has not reviewed it for safety, effectiveness or quality. It is meant to be the same molecule, mixed by a pharmacy and usually sold in a multiple-dose vial rather than a prefilled pen, typically for $150 to $400 a month, against $935 to $1,349 for the brand without insurance. Its legal room shrank sharply after the FDA declared the semaglutide shortage over in February 2025. What remains is mostly that sentence.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-compounded-ozempic-is-compared-item-by-item-with-the-brand&quot;&gt;What compounded ozempic is, compared item by item with the brand&lt;&#x2F;h2&gt;
&lt;p&gt;Start with source. Novo Nordisk makes Ozempic and Wegovy, and it holds patents covering not just the semaglutide molecule but also the formulation, the delivery device and the manufacturing process. A compounder buys active ingredient from a supplier and makes its own preparation. Where that ingredient came from is a live question. Novo, for instance, has alleged that Hims &amp;amp; Hers mass-compounded injectable versions of Wegovy made with “inauthentic API” (a phrase that tells you what the API is not, without saying what it is).&lt;&#x2F;p&gt;
&lt;p&gt;Then formulation. The brand is one specific formulation. Compounded versions vary, and some have used salt forms of semaglutide. The FDA clarified that the listing of Wegovy and Ozempic on its shortage website never authorized compounding semaglutide sodium or any other salt form. Whether those salts behave like the brand is, as far as the sources here go, not settled (the site’s article on salt forms covers that ground).&lt;&#x2F;p&gt;
&lt;p&gt;Then device, testing and legal status, which get their own sections below, because each turns out to be weird in its own way.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;reading-the-copy-rule-one-clause-at-a-time&quot;&gt;Reading the copy rule one clause at a time&lt;&#x2F;h2&gt;
&lt;p&gt;Take the sentence apart like a contract.&lt;&#x2F;p&gt;
&lt;p&gt;“Essentially a copy.” Not “a copy.” That qualifier means “a copy except in ways that do not matter,” so the whole legal fight is about which ways matter. A drug can differ from Ozempic in a dozen ways and still count, legally, as a copy of Ozempic. It can also differ in one way and not be.&lt;&#x2F;p&gt;
&lt;p&gt;“Commercially available.” During the shortage, the brand arguably was not, which is why compounders had room. Once the shortage ended, it was. Same drug, same pharmacy, different legal universe, decided by an entry on a government website (which is not how most universes get decided).&lt;&#x2F;p&gt;
&lt;p&gt;“A change made for an identified individual patient.” Every word here is singular. Identified. Individual. Patient. The statute pictures a pharmacist making something for a person with a name, maybe one who cannot tolerate an ingredient.&lt;&#x2F;p&gt;
&lt;p&gt;“Significant difference.” Significant to whom?&lt;&#x2F;p&gt;
&lt;p&gt;“As determined by the prescribing practitioner.” To the prescriber. That is the answer.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;who-decides-what-counts-as-significant&quot;&gt;Who decides what counts as significant&lt;&#x2F;h2&gt;
&lt;p&gt;Here is a second reading, and I do not think the text resolves it. One version: the prescriber’s judgment is the test, full stop, and if a licensed practitioner says the difference is significant for this patient, it is. The other version: significance is a real fact about the drug and the patient, and the prescriber is just the person whose job it is to notice it. The first reading is a bit like pickup basketball, where players call their own fouls. The second has a referee somewhere, though nobody has said where he stands.&lt;&#x2F;p&gt;
&lt;p&gt;Now a made-up scenario, clearly invented. A telehealth platform has 100,000 patients. Each gets a compounded semaglutide with the same tweak, and each prescription carries the same note saying the tweak is significant for this identified individual patient. A pharmacist calls the prescriber: “Hey, quick question, is Gary’s difference significant?” “Same as everyone’s.” “Great, and Linda?” “Also same as everyone’s.” Eventually the note is a checkbox, then the checkbox is pre-checked, then the form checks itself, and 100,000 individual determinations have been made by a dropdown menu. Each one, to be fair, is technically about an individual.&lt;&#x2F;p&gt;
&lt;p&gt;The FDA has offered its own reading, which is to count. In a warning letter reported by BioSpace, the agency found that Empower Clinic Services made tirzepatide and semaglutide products that looked like copies of approved drugs, and called the claimed differences “pretextual,” based on the company’s manufacturing volumes. So the FDA reads “individual” partly by looking at how many individuals there are (a method that is hard to argue with arithmetically). Does volume alone make a difference pretextual, or is volume just evidence that nobody was really individualizing? The letter, as reported, points at the volumes and stops.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;testing-and-the-number-79-9&quot;&gt;Testing, and the number 79.9&lt;&#x2F;h2&gt;
&lt;p&gt;The brand went through randomized trials and FDA approval. Compounded semaglutide has zero randomized trial data supporting its safety or efficacy, is not tested for safety, potency or effectiveness before use in the way approved drugs are, and has never undergone FDA bioequivalence testing, which generics must pass before approval. It is not a generic. It is a preparation.&lt;&#x2F;p&gt;
&lt;p&gt;Which brings us to a number. FDA warning letters have cited subpotent compounded semaglutide measured at 79.9% of labeled potency.&lt;&#x2F;p&gt;
&lt;p&gt;Not 80. Seventy-nine point nine.&lt;&#x2F;p&gt;
&lt;p&gt;Someone ran an assay precise enough to find the tenth of a percent, and the tenth of a percent says the vial was not quite four-fifths of what it said it was. I find this oddly moving. The measurement is excellent. It is the thing being measured that went soft. The label made a promise to one decimal place, and the lab kept it to one decimal place, and the two numbers are 20.1 points apart.&lt;&#x2F;p&gt;
&lt;p&gt;Anyway, by April 30, 2025, the FDA had received 520 adverse event reports related to compounded semaglutide. A pharmacist writing at PrecisionOptimize argues that most appear to be dosing errors rather than formulation failures. Which is the next section.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;the-pen-the-vial-and-the-milliliter-problem&quot;&gt;The pen, the vial, and the milliliter problem&lt;&#x2F;h2&gt;
&lt;p&gt;The device is where the side-by-side gets physical. Ozempic comes in a prefilled pen. Most compounded semaglutide comes in a vial with syringes. A 2023 case series of reports to a poison control center put it plainly: vials “do not include the safety features provided by prefilled manufactured pens, making large overdoses (e.g., 10-fold dosing errors) possible.” Two of its three patients self-administered 10-fold errors. One got a vial and syringes with no pharmacist counseling; one dosed in milliliters and units rather than milligrams.&lt;&#x2F;p&gt;
&lt;p&gt;On July 29, 2024, the FDA issued a MedWatch alert. The majority of its reports described patients drawing up more than the prescribed dose from a multiple-dose vial, sometimes five to 20 times more. Reported effects included nausea, vomiting, fainting, dehydration, acute pancreatitis and gallstones, some requiring hospitalization. The agency said confusion between milligrams, milliliters and syringe units may have contributed, and warned that multiple concentrations may be available. I mean, a pen is mostly a device for removing a unit conversion from someone’s kitchen. A vial hands the conversion back.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;where-the-legal-status-stands-now&quot;&gt;Where the legal status stands now&lt;&#x2F;h2&gt;
&lt;p&gt;After the shortage ended, 503A pharmacies lost broad authorization to mass-produce near-identical copies, and the FDA prohibited distribution of compounded semaglutide and tirzepatide after May 22, 2025, the same deadline set for 503B outsourcing facilities. That leaves, look, the sentence we started with.&lt;&#x2F;p&gt;
&lt;p&gt;The market did not entirely notice. In one secret shopper study of 75 businesses, 92% sold compounded semaglutide. The FDA sent warning letters to telehealth sellers in rounds dated September 2025, February 2026 and June 2026. Hims &amp;amp; Hers advertised a compounded semaglutide tablet launch on February 5, 2026, and on February 9 Novo Nordisk sued it for infringing US Patent No. 8,129,343 (four days being, presumably, simply how long the mail takes). Novo was, in its understated way, unenthusiastic. How that case ends is not settled.&lt;&#x2F;p&gt;
&lt;p&gt;On the other hand, the price gap is the whole engine. Brand semaglutide can run upwards of $1,300 a month out of pocket; compounded versions in San Antonio ran $150 to $300 in 2026. It’s fine to notice that a gap that size makes people read statutes very carefully.&lt;&#x2F;p&gt;
&lt;p&gt;Read literally, the most legally durable compounded semaglutide business in America has exactly one customer, and his name is on the vial.&lt;&#x2F;p&gt;
</content>
        
    </entry>
    <entry xml:lang="en">
        <title>What FDA Inspectors Write Down at Compounding Pharmacies</title>
        <published>2026-11-01T00:00:00+00:00</published>
        <updated>2026-11-01T00:00:00+00:00</updated>
        
        <author>
          <name>
            
              Unknown
            
          </name>
        </author>
        
        <link rel="alternate" type="text/html" href="https://compoundglp.com/fda-483-compounding-inspections/"/>
        <id>https://compoundglp.com/fda-483-compounding-inspections/</id>
        
        <content type="html" xml:base="https://compoundglp.com/fda-483-compounding-inspections/">&lt;p&gt;Today the most common thing FDA inspectors write down at outsourcing facilities (the 503B kind of compounder) is a complaint about how they make the drugs. A review of FDA Form 483 data presented at the FDA Compounding Quality Center of Excellence’s 2024 conference found production and process control deficiencies in close to 29 percent of all observations issued to outsourcing facilities. Facility control systems came second at roughly 13 percent, environmental and personnel monitoring gaps at about 11 percent, and packaging and labeling defects at roughly 9 percent.&lt;&#x2F;p&gt;
&lt;p&gt;So if you typed fda 483 compounding into a search box, that is the short answer. A Form 483 is the list of observations an inspector leaves with a facility at the end of an inspection, and at compounders the list is mostly about process, monitoring and labels. The longer answer is that a 483 is the opening move rather than the verdict. In the GLP-1 business, a striking share of the FDA’s written output has also been about words on websites rather than particles in vials.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-an-fda-483-at-a-compounding-pharmacy-is-and-what-it-isn-t&quot;&gt;What an FDA 483 at a compounding pharmacy is, and what it isn’t&lt;&#x2F;h2&gt;
&lt;p&gt;The sensible reaction is: of course. Compounders make sterile injectable drugs, and inspectors check whether they make them cleanly. So when the FDA cracks down on compounded semaglutide and tirzepatide, it is presumably because it found dirty rooms. That’s a reasonable guess. Some of it is even right.&lt;&#x2F;p&gt;
&lt;p&gt;But the mechanism is a bit odder. A 483 works like the form the rental car agent fills out when you return the car. She walks around it, notes the scratch on the bumper (and the faint smell of french fries), and hands you a copy. That is not a judgment that you are a bad driver. It is a list of things she saw, and what happens next depends a lot on what you say about the scratch.&lt;&#x2F;p&gt;
&lt;p&gt;What you say is where it goes wrong. BioSpace ran a headline about the FDA’s worry over contaminating drugs “with filth” (a phrase that does a lot of work in a headline). It reported that Empower Clinic Services’ response to the FDA’s Form 483 observations about insanitary conditions failed to satisfy the agency, which noted “gaps and discrepancies” in the paperwork submitted. So the inspector writes down what she saw, the facility writes back about what it fixed, and the agency grades the second document. In some sense the thing being inspected is the homework about the homework.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-inspectors-write-down-most-often&quot;&gt;What inspectors write down most often&lt;&#x2F;h2&gt;
&lt;p&gt;Those percentages (29, 13, 11 and 9, adding up to about 62) are for outsourcing facilities generally, not GLP-1 makers specifically. The facts I have do not break out the remaining third or so. They also don’t describe the corner pharmacy. 503A compounding pharmacies are regulated primarily by state boards of pharmacy rather than the FDA, and they are not required to register with the FDA or follow the Current Good Manufacturing Practices that drug manufacturers must meet. The federal 483 tally is basically a portrait of the 503Bs.&lt;&#x2F;p&gt;
&lt;p&gt;Translated out of inspection language, the categories are: the process for making the drug, the building it is made in, the checks on the air and the people, and the label. Which is the whole drug.&lt;&#x2F;p&gt;
&lt;p&gt;The more vivid catalog shows up in warning letters. On September 18, 2026, the FDA sent a warning letter to a Houston compounding pharmacy citing, among other things, sterile compounding failures including inadequate smoke studies and rewritten media fill records. A smoke study is what it sounds like: you release visible smoke in the clean work area and film it, to show that air flows away from the open vial rather than toward it. A media fill is a dress rehearsal (nutrient broth standing in for the drug) to see whether anything grows. Both exist to produce a record, and that’s fine. Records are how a regulator who is not in the room every day can know anything at all. “Hey, can I see the smoke study video?” is something an investigator says, I’d guess, at most sterile inspections.&lt;&#x2F;p&gt;
&lt;p&gt;A rewritten record is a different problem. The whole point of a media fill is that the broth either grew something or it didn’t, and the record is supposed to be the one part of the process that has no opinion.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;why-the-prescriptions-themselves-got-written-up&quot;&gt;Why the prescriptions themselves got written up&lt;&#x2F;h2&gt;
&lt;p&gt;The same Houston letter cited something less physical: pretextual significant-difference determinations and boilerplate prescribing records. In plain words: you generally may not make a copy of a drug people can buy. You may make something for a patient who needs it to be a bit different. And the paperwork for a great many patients said, in the same sentence each time, that they needed it to be a bit different. The official name for this is a “pretextual significant-difference determination,” and the prescribing setup that produced it was, let’s say, very accommodating.&lt;&#x2F;p&gt;
&lt;p&gt;The background is the copy rule. In 2018, Pharmacy Times has noted, the FDA published guidance to 503A pharmacies on what counts as unauthorized compounding of a copy of an approved product. Compounding a copy is ordinarily prohibited, but the shortage exception permitted GLP-1 compounding while semaglutide and tirzepatide were on the FDA drug shortage list. Then the shortages ended. For semaglutide, the FDA’s February 21, 2025 declaratory order gave 503A pharmacies until April 22, 2025, and 503B facilities until May 22, 2025, to stop compounding under the exception. According to Legal 500, the agency said the delay was meant “to allow patients a reasonable amount of time to transfer their prescriptions.” (The tirzepatide version, with its court ruling and moving deadlines, lives in another article.)&lt;&#x2F;p&gt;
&lt;p&gt;Once the exception is gone, the significantly-different door is the only door, and the only door gets a lot of traffic. Here is a made-up example of where that ends. A pharmacy’s intake form adds a field: “Clinical reason this patient requires a non-commercial formulation.” The field autofills. Ten thousand patients in a row require it for the same reason, typed identically (including the typo). Eventually the typo is load-bearing, since fixing it would technically be a change in clinical documentation. An inspector reads the stack and writes down, in the flattest prose available, “boilerplate.”&lt;&#x2F;p&gt;
&lt;h2 id=&quot;why-so-many-glp-1-warning-letters-are-about-advertising&quot;&gt;Why so many GLP-1 warning letters are about advertising&lt;&#x2F;h2&gt;
&lt;p&gt;Now the part the objection doesn’t predict. On September 9, 2025, the FDA sent more than 50 warning letters to GLP-1 compounders and online sellers citing misbranding under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. Section 502(bb) is a compounding-specific provision prohibiting false or misleading advertising or promotion of a compounded drug. Another trade report counted more than 55 warning letters to online sellers on September 16, 2025. Whether that is the same wave counted differently or a second one, I don’t know, and the sources don’t settle it.&lt;&#x2F;p&gt;
&lt;p&gt;The letters name the telehealth platform itself, not just the pharmacy, as the party responsible for misbranding. The reasoning, set out with the gravity it deserves, runs as follows. First premise: the FDA’s position is that compounding facilities, including pharmacies and outsourcing facilities, are not FDA-approved or FDA-licensed entities. Second premise: a website says or suggests that they are. Conclusion: the website is misbranding a drug, and whoever runs the website is the one doing it. The proof fits on an index card, and delivering it still took more than 50 letters, I guess.&lt;&#x2F;p&gt;
&lt;p&gt;It kept going. In March 2026, the FDA issued 30 warning letters to telehealth companies offering GLP-1 products with misleading claims. In April 2026, as ArentFox Schiff described it, a second round targeted companies marketing unapproved GLP-1, dual GLP-1&#x2F;GIP and triple agonist products, “many labeled ‘research use only.’” Research use only is the pharmaceutical cousin of the old commercial that opened with “I’m not a doctor, but I play one on TV.” Everyone understands the disclaimer. The agency, judging by the letters, was not persuaded that the disclaimer was the part customers were reading.&lt;&#x2F;p&gt;
&lt;p&gt;I write about pharmacy paperwork for a living, which mostly means reading letters addressed to other people, and the striking thing about this pile is how little of it is about chemistry. The 483s describe clean rooms and airflow. The warning letters increasingly describe landing pages, checkout flows, or whatever the sales funnel looked like that quarter, sort of thing.&lt;&#x2F;p&gt;
&lt;p&gt;Which makes the website the most thoroughly inspected room in the business.&lt;&#x2F;p&gt;
</content>
        
    </entry>
    <entry xml:lang="en">
        <title>Is Compounded Semaglutide Safe? What the Evidence Shows</title>
        <published>2026-11-01T00:00:00+00:00</published>
        <updated>2026-11-01T00:00:00+00:00</updated>
        
        <author>
          <name>
            
              Unknown
            
          </name>
        </author>
        
        <link rel="alternate" type="text/html" href="https://compoundglp.com/is-compounded-semaglutide-safe/"/>
        <id>https://compoundglp.com/is-compounded-semaglutide-safe/</id>
        
        <content type="html" xml:base="https://compoundglp.com/is-compounded-semaglutide-safe/">&lt;p&gt;One thing that happens when a drug reaches millions of people without a clinical trial is that its safety record gets assembled afterward, out of whatever people happen to report. Compounded semaglutide is the clearest current example. If you typed “is compounded semaglutide safe” into a search box, the honest answer is that nobody has run the study that would settle it. The site Compounded Semaglutide Dosage Chart notes that the product “is not FDA-approved as a finished drug product and has not been reviewed by the FDA for safety, effectiveness, or quality,” and a regulatory explainer, Compounded Semaglutide: Meaning and Why Regulators Warn, says it “has zero randomized trial data supporting its safety or efficacy.”&lt;&#x2F;p&gt;
&lt;p&gt;What does exist is a pile of after-the-fact evidence: FDA adverse event reports (520 of them related to compounded semaglutide by April 30, 2025), poison control case reports, and FDA inspection findings about what was in the vials. Most of that evidence describes one specific failure. People drew up the wrong amount from a multi-dose vial, sometimes five to 20 times the intended dose. Problems with the drug itself (weak potency, unapproved salt forms) are documented too, but whether they hurt anyone, and how often, is not settled.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;is-compounded-semaglutide-safe-and-what-would-count-as-an-answer&quot;&gt;Is compounded semaglutide safe, and what would count as an answer&lt;&#x2F;h2&gt;
&lt;p&gt;For purposes of this article, and with the gravity the subject deserves, “safe” shall mean that a drug has been tested in controlled conditions, compared against something, and found to do what it says without doing too much else. Under that definition the question cannot be answered in the affirmative, because the test was never held. Compounded semaglutide “is not tested for safety, potency, or effectiveness before use,” per the same explainer. A pharmacist writing at PrecisionOptimize adds that it “has never undergone FDA bioequivalence testing,” which generics have to do.&lt;&#x2F;p&gt;
&lt;p&gt;That leaves a weaker definition: safe enough, judged by how often reports of harm show up. That is the definition the actual evidence speaks to. It is a different question.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;who-gets-paid-at-each-step-from-shortage-to-syringe&quot;&gt;Who gets paid at each step from shortage to syringe&lt;&#x2F;h2&gt;
&lt;p&gt;Start with Novo Nordisk, which sells semaglutide in prefilled pens. A pen basically decides the dose for you. Then demand outran supply, semaglutide went on the FDA shortage list, and the law let compounders make their own versions while the shortage lasted. Compounders were filling a real gap, which is what the shortage rules are for.&lt;&#x2F;p&gt;
&lt;p&gt;What they sold was usually a vial and some syringes. Telehealth brands built businesses on selling those vials, typically for between $150 and $400 a month. To be fair to everyone, a patient choosing that over the branded price was making an entirely sensible choice, and a company offering it was doing the obvious thing a company does.&lt;&#x2F;p&gt;
&lt;p&gt;The trouble is the format. A case series reported to a poison control center put it this way: “Vials of compounded semaglutide do not include the safety features provided by prefilled manufactured pens, making large overdoses (e.g., 10-fold dosing errors) possible.” A pen is like a coffee machine that takes pods. A vial is a bag of beans and an unmarked scoop. Both make coffee.&lt;&#x2F;p&gt;
&lt;p&gt;One link down, the patient has to do arithmetic. The prescription is in milligrams, the vial is labeled by concentration in milligrams per milliliter, and the syringe is marked in units. The FDA said confusion among those three “may have contributed” to dosing errors. This is the Stonehenge scene in Spinal Tap, where a drawing in inches gets built in feet, except the miniature version is the one you wanted. In the 2023 case series, one patient got a vial and syringes with no pharmacist counseling at all, and another dosed in milliliters and units rather than milligrams. (I write about syringe units for a living and would still want someone to check my work.)&lt;&#x2F;p&gt;
&lt;p&gt;The next link is poison control. Calls about injected weight loss drugs rose more than 15-fold since 2019, with many relating to dosing errors more common with compounded multi-dose vials. Then the FDA, which collects reports. Then Novo Nordisk, which by August 5, 2025 had filed 132 complaints in federal courts across 40 states, citing patient safety. (Its press release puts “semaglutide” in scare quotes when referring to the compounded kind, a typographical decision I will simply admire and not interpret.) On the other hand, Novo selling the pens and suing the vials is also just a company doing the obvious thing a company does.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-the-poison-control-and-fda-reports-actually-show&quot;&gt;What the poison control and FDA reports actually show&lt;&#x2F;h2&gt;
&lt;p&gt;On July 29, 2024, the FDA issued a MedWatch alert about dosing errors with compounded injectable semaglutide. The agency said the majority of its reports described patients “mistakenly drawing up more than the prescribed dose from a multiple-dose vial during self-administration.” Patients took five to 20 times the intended amount. Some were hospitalized. Reported effects included nausea, vomiting, abdominal pain, fainting, headache, migraine, dehydration, acute pancreatitis and gallstones.&lt;&#x2F;p&gt;
&lt;p&gt;The FDA also warned that multiple concentrations may be on the market and told providers to call the compounder if they were unsure. That is a sensible instruction. It also tells you something about the market.&lt;&#x2F;p&gt;
&lt;p&gt;Here is an invented scenario, clearly not something that happened. A compounder makes its vial twice as concentrated, so it ships less liquid. A competitor doubles again. Eventually one syringe tick is a month of drug, and the pharmacist at the counter says, “So you just want to sort of think about it and inject a little bit.” Nobody in this chain made a bad decision. The chain did.&lt;&#x2F;p&gt;
&lt;p&gt;The 2023 case series is small: three patients, from compounding pharmacies and an aesthetic spa, two of whom gave themselves 10-fold errors. The point is that small case series are what you get when there is no trial.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-testing-and-inspections-found-inside-the-vials&quot;&gt;What testing and inspections found inside the vials&lt;&#x2F;h2&gt;
&lt;p&gt;The drug itself is a separate question, and the evidence is thinner. FDA warning letters have cited compounded semaglutide measured at 79.9% of labeled potency. Early safety signals included unapproved salt forms, semaglutide sodium and semaglutide acetate, and non-sterile compounding environments. No clinical studies show that those salt forms behave like the semaglutide base used in research. The FDA also found that Empower Clinic Services made semaglutide and tirzepatide products that looked like copies of approved drugs.&lt;&#x2F;p&gt;
&lt;p&gt;On sourcing, a Brookings Institution report cited by Novo said many products rely on active ingredients imported from facilities in China lacking FDA oversight. Novo also alleged Hims &amp;amp; Hers used “inauthentic API,” and sued Hims &amp;amp; Hers on February 9, 2026, for patent infringement. Those are allegations in a lawsuit, not findings. The site’s article on independent lab testing covers the testing results in detail.&lt;&#x2F;p&gt;
&lt;p&gt;The PrecisionOptimize pharmacist’s read is that most MedWatch events for compounded semaglutide “appear to be dosing errors rather than formulation failures.” I assume that is roughly right as a description of the reports. It is not the same as saying formulations are fine.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-the-faers-studies-can-and-cannot-tell-you&quot;&gt;What the FAERS studies can and cannot tell you&lt;&#x2F;h2&gt;
&lt;p&gt;FAERS is the FDA’s adverse event reporting database, and it is voluntary (which is a polite way of saying it counts whoever bothered). A pharmacovigilance study (PMID 40285721) looked at compounded liraglutide, semaglutide and tirzepatide reports from 2018 to 2024; its specific findings are not in the material here, so I won’t characterize them. A larger study covering 2021 through early 2026 found 243,114 GLP-1 primary-suspect records, 55,619 of them semaglutide, with “incorrect dose administered” among the frequent terms. That count covers GLP-1s generally, not just compounded ones.&lt;&#x2F;p&gt;
&lt;p&gt;I mean, think about what FAERS can capture. A dramatic overdose sends someone to a hospital, and someone files a report. A vial at 79.9% potency mostly produces a patient who loses less weight and assumes it is them. Weak drug is quiet. Ten times the drug is loud.&lt;&#x2F;p&gt;
&lt;p&gt;So the database is, for instance, much better at counting syringe mistakes than at detecting a slightly wrong product. Whether the formulation problems cause harm at a meaningful rate is not something these reports can settle.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;why-the-evidence-ends-up-being-about-arithmetic&quot;&gt;Why the evidence ends up being about arithmetic&lt;&#x2F;h2&gt;
&lt;p&gt;The semaglutide shortage ended in February 2025, and the FDA’s deadline for 503B facilities to stop new batches was May 22, 2025. The FDA declined to put semaglutide on the 503B bulks list. Some sellers kept going anyway: a secret shopper study found 92% of 75 businesses selling compounded semaglutide, and the FDA sent telehealth warning letters in September 2025, February 2026 and June 2026. Hims &amp;amp; Hers advertised a compounded semaglutide tablet on February 5, 2026. Tablets, at least, do not come with syringe units.&lt;&#x2F;p&gt;
&lt;p&gt;Each party here did something reasonable. The result is that the best-documented safety question about compounded semaglutide is not about the semaglutide at all.&lt;&#x2F;p&gt;
&lt;p&gt;It is about how the vial meets the syringe, which means the most thorough safety record this drug has is a national survey of how people read the side of a syringe.&lt;&#x2F;p&gt;
</content>
        
    </entry>
    <entry xml:lang="en">
        <title>How to Judge a Compounding Pharmacy&#x27;s Quality</title>
        <published>2026-11-01T00:00:00+00:00</published>
        <updated>2026-11-01T00:00:00+00:00</updated>
        
        <author>
          <name>
            
              Unknown
            
          </name>
        </author>
        
        <link rel="alternate" type="text/html" href="https://compoundglp.com/judge-a-compounding-pharmacy/"/>
        <id>https://compoundglp.com/judge-a-compounding-pharmacy/</id>
        
        <content type="html" xml:base="https://compoundglp.com/judge-a-compounding-pharmacy/">&lt;p&gt;The most respected credential a compounding pharmacy can earn is one it is not required to have. The Pharmacy Compounding Accreditation Board, or PCAB, runs a voluntary accreditation program, which a consumer explainer titled “Is your compounded semaglutide and tirzepatide safe?” describes as “an extra optional step that some compounding pharmacies take to be legitimized by a third party.” A pharmacy that skips it is still a pharmacy. There is no federal ranking, no league table and no official list of the good ones.&lt;&#x2F;p&gt;
&lt;p&gt;So if you typed best compounding pharmacy into a search box, the plain answer is that nobody publishes that list, and the facts available here cannot produce one. What exists instead is a short set of things that can be checked: whether the pharmacy is accredited (by PCAB, mostly), whether it follows USP 797, the sterile-compounding chapter, how it tests what it makes, and where its active ingredient comes from. Those four things are roughly what “quality” means in this business. There is a simple way to evaluate them and a sophisticated way, and they end up in the same place.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;why-nobody-ranks-the-best-compounding-pharmacy&quot;&gt;Why nobody ranks the best compounding pharmacy&lt;&#x2F;h2&gt;
&lt;p&gt;The market is big and the referees are scattered. At the peak in 2024, nearly one in three Americans taking a GLP-1 drug reported getting it from a compounding pharmacy, and the whole U.S. compounding market was valued at about $6.98 billion in 2025, with projections of $12.79 billion by 2035. That is a lot of vials.&lt;&#x2F;p&gt;
&lt;p&gt;Meanwhile, 503A pharmacies (the traditional, patient-specific kind) are regulated mainly by state boards of pharmacy rather than the FDA, and they are not required to register with the FDA or follow the Current Good Manufacturing Practices that drug manufacturers must meet. So the referee is fifty different referees. Each one is grading a different game.&lt;&#x2F;p&gt;
&lt;p&gt;Everyone here is acting sensibly from where they sit. A state board inspects the pharmacies it licenses, the FDA focuses on what federal law hands it, and a pharmacy invests in whatever credential the people paying it actually ask about. Nobody’s job description includes “publish a ranking.”&lt;&#x2F;p&gt;
&lt;h2 id=&quot;the-simple-version-look-for-the-sticker&quot;&gt;The simple version: look for the sticker&lt;&#x2F;h2&gt;
&lt;p&gt;The simple way to judge a compounder is to ask whether it has PCAB accreditation. If yes, good. If no, less good. It’s fine.&lt;&#x2F;p&gt;
&lt;p&gt;And the sticker does mean something: an outside party came and looked. The accreditation is optional, so having it tells you the pharmacy chose to be looked at. Well, mostly chose. Washington and Ohio now require verifiable PCAB accreditation for nonresident compounding pharmacy licensure, so the stricter thing to say is that PCAB is optional the way a passport is optional. Nobody needs one to stay home, but a pharmacy that wants to ship into Washington or Ohio from another state has to have it. Some of the most voluntary-looking stickers in the industry are really travel documents.&lt;&#x2F;p&gt;
&lt;p&gt;That is the dumb version. Its weakness is that it outsources the judgment to someone else. Its strength is the same.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;the-sophisticated-version-read-the-rulebook&quot;&gt;The sophisticated version: read the rulebook&lt;&#x2F;h2&gt;
&lt;p&gt;The sophisticated way is to skip the sticker and ask what rules the pharmacy actually lives under. A 503A pharmacy must comply with USP 795 (nonsterile compounding) and USP 797 (sterile compounding), plus its state board’s regulations. It is exempt from the federal cGMP framework in 21 CFR Parts 210 and 211 when it compounds for a patient-specific prescription. A 503B outsourcing facility, on the other hand, must validate every process under cGMP.&lt;&#x2F;p&gt;
&lt;p&gt;Here is a concrete difference. Every compounded drug gets a beyond-use date, which is basically the pharmacy’s version of an expiration date. A 503A pharmacy may rely on default date categories set out in USP 797. The FDA’s draft cGMP guidance for outsourcing facilities expects those dates to be backed by stability data for the specific formulation. One tier uses the standard chart, and the other has to prove its own numbers.&lt;&#x2F;p&gt;
&lt;p&gt;The stricter tier is not spotless either. A review of FDA Form 483 data (the list of problems inspectors write down on site) presented at the FDA Compounding Quality Center of Excellence’s 2024 conference found production and process control deficiencies in close to 29 percent of all observations issued to outsourcing facilities. Nearly three in ten. Under the strict rules.&lt;&#x2F;p&gt;
&lt;p&gt;Then there is the paperwork. On September 18, 2026, the FDA sent a warning letter to a Houston compounding pharmacy citing pretextual significant-difference determinations, boilerplate prescribing records, and sterile compounding failures including “inadequate smoke studies and rewritten media fill records.” A smoke study shows how air moves around the sterile work area. A media fill is a rehearsal of the compounding process using a growth medium, to see whether anything grows. The point of both is a record that shows the room works. (The point is not a record that shows the room works after some editing.) I mean, one imagines the inspection going something like this, in invented dialogue: “Hey, can we see the media fill records?” “Sure. Which draft?” It must be tiring to keep improving documents that were presumably fine the first time.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;where-the-active-ingredient-comes-from&quot;&gt;Where the active ingredient comes from&lt;&#x2F;h2&gt;
&lt;p&gt;Federal law gives a 503A pharmacy exactly three ways to use a bulk drug substance: it meets an applicable USP or National Formulary monograph, it is a component of an FDA-approved drug, or it appears on a list the FDA developed. Semaglutide has no monograph. The sodium and acetate salt forms fail all three tests: no monograph, not part of any approved drug, not on the list. On April 27, 2023, the FDA told the National Association of Boards of Pharmacy it was not aware of any basis for compounding with those salts that would satisfy federal requirements. The Mississippi Board of Pharmacy put it in writing to its licensees, warning that salt compounding “may draw action from FDA or the board itself.” (The site’s piece on salt forms covers the chemistry.) Presumably every pharmacy that used the salts did so for their fine chemical properties, and not because they were the semaglutide on offer that week.&lt;&#x2F;p&gt;
&lt;p&gt;For ingredients that do qualify, the rule is that a 503A pharmacy compounding from a bulk substance must buy from a registered manufacturer and get a valid certificate of analysis. The certificate is a document from the supplier saying what is in the drum. This works a lot like the itemized receipt a restaurant staples to a delivery bag. It is useful and specific, and it was printed by the restaurant.&lt;&#x2F;p&gt;
&lt;p&gt;Which is why the origin question gets asked. A Brookings Institution report, cited by Novo Nordisk (which sells brand semaglutide and sues compounders, so it has a view), said many compounded semaglutide products rely on API imported from facilities in China that lack FDA oversight or quality controls. How many, exactly, is not settled by the facts here; the percentage Novo quotes is described in its own source as incomplete.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-testing-does-and-does-not-tell-you&quot;&gt;What testing does and does not tell you&lt;&#x2F;h2&gt;
&lt;p&gt;The facts here do not settle how often a 503A pharmacy must test its finished product, or by whose lab. What they do show is a ladder: supplier certificates at the bottom, default dating under USP 797 for 503A pharmacies, and formulation-specific stability data expected of outsourcing facilities. Each rung is more evidence produced by the party being judged, or by its vendor.&lt;&#x2F;p&gt;
&lt;p&gt;And quality does not stop at the vial. In a 2023 poison-control case series on compounded semaglutide errors, one patient reported receiving a vial and syringes for self-administration with no pharmacist counseling on how to use them. That is a weird gap for a sterile process to have at the very end. (The site’s piece on dosing errors has the rest.)&lt;&#x2F;p&gt;
&lt;p&gt;Now a made-up scenario, purely illustrative. Suppose a patient decides to run the sophisticated version personally. She requests the certificate of analysis, then the supplier’s registration, then flies to the API plant to watch a batch, then buys a fog machine to run her own smoke study on the pharmacy’s hood, then asks to rehearse a media fill herself, then sits in the clean room for a fourteen-day incubation reading Yelp reviews of other clean rooms. She has now audited one vial. Lol.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;how-the-two-versions-end-up-in-the-same-place&quot;&gt;How the two versions end up in the same place&lt;&#x2F;h2&gt;
&lt;p&gt;Look, the simple version says: trust the sticker. The sophisticated version says: trust the records. But the sticker is just someone else having read the records, and the records are written by the pharmacy, about the pharmacy. The long road and the short road both end at the same desk, reading the same binder.&lt;&#x2F;p&gt;
&lt;p&gt;Anyway, the regulators have noticed that the binder sometimes comes from far away. FDA warning letters to telehealth companies name the platform itself, not just the compounding pharmacy, as responsible for misbranding the drug. So even the question of whose pharmacy it is has gotten complicated.&lt;&#x2F;p&gt;
&lt;p&gt;The best compounding pharmacy is the one whose records are true.&lt;&#x2F;p&gt;
</content>
        
    </entry>
    <entry xml:lang="en">
        <title>The Semaglutide Shortage: How a Drug Gets on the List and Off It</title>
        <published>2026-11-01T00:00:00+00:00</published>
        <updated>2026-11-01T00:00:00+00:00</updated>
        
        <author>
          <name>
            
              Unknown
            
          </name>
        </author>
        
        <link rel="alternate" type="text/html" href="https://compoundglp.com/semaglutide-shortage/"/>
        <id>https://compoundglp.com/semaglutide-shortage/</id>
        
        <content type="html" xml:base="https://compoundglp.com/semaglutide-shortage/">&lt;p&gt;For about three years, whether an American pharmacy could legally make its own copy of a blockbuster weight-loss drug depended on whether that drug’s name appeared on a list kept by the Food and Drug Administration. Wegovy, which the FDA approved in June 2021, was added to the FDA drug shortage list on March 31, 2022, and Ozempic followed in August 2022. The semaglutide shortage, in the legal sense that mattered to compounders, ended on February 21, 2025, when the FDA issued a 13-page declaratory order determining that it had been resolved.&lt;&#x2F;p&gt;
&lt;p&gt;So the plain answer is that, officially, semaglutide injection products have not been in shortage since that order. Compounders got a wind-down: state-licensed 503A pharmacies had until April 22, 2025, and 503B outsourcing facilities had until May 22, 2025, to stop compounding under the shortage exception. A trade group sued three days after the order, and the U.S. Court of Appeals for the Fifth Circuit upheld the FDA’s removal of both semaglutide and tirzepatide, as reported in September 2026. That part is settled.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;why-a-list-and-not-the-pharmacy-shelf-decides-who-can-compound&quot;&gt;Why a list, and not the pharmacy shelf, decides who can compound&lt;&#x2F;h2&gt;
&lt;p&gt;The sensible reaction to all this is that a shortage is a fact about the world. Either patients can fill their prescriptions or they can’t. It seems odd for the legality of an entire industry to hinge on a government web page rather than on whether the pens are actually at the pharmacy, and if you were designing the system from scratch you might well make it hinge on the pens.&lt;&#x2F;p&gt;
&lt;p&gt;To be fair to that objection, the law starts from something like it. Compounding a copy of an approved drug is ordinarily prohibited, but Sections 503A and 503B of the Food, Drug, and Cosmetic Act carve out an exception for drugs in shortage. And Legal 500 notes that “the FDA is required by statute to maintain an up-to-date list of drugs determined to be in shortage in the United States.” So there is a real-world fact, and there is a list meant to track it.&lt;&#x2F;p&gt;
&lt;p&gt;The strange part is which one the exception points to. It points to the list. Compounding a drug identical or nearly identical to an approved product is allowed only while that product appears on the FDA drug shortage list at the time of compounding, distribution, and dispensing (three separate moments, each of which has to check out). Not while it is hard to find, or while patients are complaining. While it is listed.&lt;&#x2F;p&gt;
&lt;p&gt;You and I would use “shortage” to mean you went to the pharmacy and they didn’t have it. The statute uses it more the way a parking sign uses “no parking”: the sign is the rule, whatever the traffic happens to be doing. The point is that, for legal purposes, the list is not evidence of the shortage. It is the shortage. (I write about finance, where the most consequential fact about a company is often which index it has been added to, so I find this extremely relaxing, which is probably a bad sign about my job.)&lt;&#x2F;p&gt;
&lt;h2 id=&quot;how-semaglutide-got-on-the-list-and-what-that-unlocked&quot;&gt;How semaglutide got on the list, and what that unlocked&lt;&#x2F;h2&gt;
&lt;p&gt;Demand for semaglutide and tirzepatide outstripped supply in 2022, both drugs went on the list, and compounding pharmacies entered the market that year. The law firm ArentFox Schiff describes what grew from there as a “multibillion-dollar sub-industry.” (The “sub” is doing modest work in that phrase.)&lt;&#x2F;p&gt;
&lt;p&gt;The mechanics differ by type of compounder, which other pieces on this site cover. The short version for 503B outsourcing facilities is that they may compound large volumes of drugs from bulk drug substances without individual patient prescriptions, if the drug is on the shortage list at the time of compounding, distribution, and dispensing. That is a manufacturing business, more or less, switched on by a line of text on a federal website.&lt;&#x2F;p&gt;
&lt;p&gt;The Health Law Alliance, in an August 2026 article, puts the dependency bluntly: the shortage-list exception, “not any general right to compound popular medications,” is what permitted large-scale compounding of semaglutide and tirzepatide for several years. Popularity was the demand. The list was the permission.&lt;&#x2F;p&gt;
&lt;p&gt;The list also didn’t authorize everything done in its name. The FDA clarified that listing Wegovy and Ozempic did not authorize compounding semaglutide sodium or any other salt form (a separate mess, with its own article). And America’s Poison Centers notes that shortage-era compounded GLP-1s “are not reviewed by the FDA for safety or efficacy.” The list switched on legality. It did not switch on review.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;how-the-semaglutide-shortage-ended-a-declaratory-order-and-a-wind-down&quot;&gt;How the semaglutide shortage ended: a declaratory order and a wind-down&lt;&#x2F;h2&gt;
&lt;p&gt;Getting off the list works through a document. Per the same Health Law Alliance article, FDA shortage determinations are declaratory orders that identify “the specific drug, dosage form, and strength being removed from the shortage list, and take effect on the date issued.” In other words, the FDA writes down that the shortage is over. Then it is over.&lt;&#x2F;p&gt;
&lt;p&gt;Tirzepatide went first, by declaratory order on December 19, 2024 (one source gives October 2, 2024, and the records conflict on this). Semaglutide followed on February 21, 2025.&lt;&#x2F;p&gt;
&lt;p&gt;This is where “compounding, distribution, and dispensing” gets interesting, so here is a scenario, entirely made up. An outsourcing facility fills a batch of vials on a Thursday while semaglutide is listed. Friday morning the order issues. On a strict reading, the vials were lawfully compounded and can no longer be lawfully distributed, so a box on a truck somewhere in Ohio crosses from legal to not legal while stopped at a red light, and a pharmacist has to work out whether dispensing happens when the vial leaves the shelf or when it leaves her hand. Meanwhile a compliance officer is telling a colleague, “Okay, refresh the page. Still on there? Refresh it again.”&lt;&#x2F;p&gt;
&lt;p&gt;The FDA did not make anyone litigate the red light. It used enforcement discretion to give 503A pharmacies a 60-day wind-down, to April 22, 2025, and 503B facilities until May 22, 2025. I mean, it’s fine. It is what a reasonable regulator would do; it is just notable that the reasonable thing had to arrive as a grace period layered on a rule that, read literally, contains no grace at all.&lt;&#x2F;p&gt;
&lt;p&gt;After the window, by one account, a 503B could use bulk semaglutide only if it appeared on the FDA’s bulk substances list or the shortage list, and at the time that account was written semaglutide was on neither. Whether that has changed is not something these sources settle.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;why-the-compounders-sued-and-what-the-fifth-circuit-said&quot;&gt;Why the compounders sued, and what the Fifth Circuit said&lt;&#x2F;h2&gt;
&lt;p&gt;On February 24, 2025, three days after the order, the Outsourcing Facilities Association sued the FDA in Fort Worth, Texas. It had already brought a similar case over tirzepatide. The argument was about procedure: the challengers said the FDA should have used notice-and-comment rulemaking before taking the drugs off the list.&lt;&#x2F;p&gt;
&lt;p&gt;Why fight about procedure instead of pens? Because the objection at the top of this piece cuts both ways. If the list merely recorded a fact, you would fight about the fact. But if the list is the legal switch, the interesting question becomes who gets to flip it and how much ceremony comes first. Notice-and-comment takes time, and for instance a few extra months of listing would be a few extra months for a business that otherwise had a deadline.&lt;&#x2F;p&gt;
&lt;p&gt;I assume the association’s devotion to the finer points of administrative procedure is deep and long-standing, and that its urgency landing on the same week a multibillion-dollar business received a wind-down date is the sort of coincidence administrative law produces all the time.&lt;&#x2F;p&gt;
&lt;p&gt;Anyway, it didn’t work. The Fifth Circuit upheld the FDA’s determinations on both drugs, as reported in September 2026. The agency can declare a shortage over, by order, and it is over.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;why-a-drug-can-be-available-and-still-on-the-list&quot;&gt;Why a drug can be available and still on the list&lt;&#x2F;h2&gt;
&lt;p&gt;The gap between the list and the shelf runs in the other direction too. As of February 2025, according to Foley &amp;amp; Lardner, dulaglutide was still on the shortage list even though its manufacturer reported all presentations were available. Liraglutide was still listed as well, with two presentations reported available and three with limited availability.&lt;&#x2F;p&gt;
&lt;p&gt;On the other hand, this is just what happens when a fact about the world becomes a legal status by way of a document: the status changes when the document changes, not when the pens show up (or stop showing up). Whatever was happening at pharmacies in the weeks before, semaglutide’s legal shortage ended on February 21, 2025, because that is the day the order was issued.&lt;&#x2F;p&gt;
&lt;p&gt;So in February 2025, by the only definition the statute cares about, the scarcest thing about dulaglutide was the paperwork saying there was plenty of it.&lt;&#x2F;p&gt;
</content>
        
    </entry>
    <entry xml:lang="en">
        <title>Semaglutide Sodium and Acetate: Why the Salt Form Matters</title>
        <published>2026-11-01T00:00:00+00:00</published>
        <updated>2026-11-01T00:00:00+00:00</updated>
        
        <author>
          <name>
            
              Unknown
            
          </name>
        </author>
        
        <link rel="alternate" type="text/html" href="https://compoundglp.com/semaglutide-sodium/"/>
        <id>https://compoundglp.com/semaglutide-sodium/</id>
        
        <content type="html" xml:base="https://compoundglp.com/semaglutide-sodium/">&lt;p&gt;On April 27, 2023, the Food and Drug Administration told the National Association of Boards of Pharmacy that it had thought about a particular chemical and could not come up with a reason for anyone to be using it. The chemical was semaglutide sodium, along with its cousin semaglutide acetate, and the use was compounding: pharmacies making their own versions of Ozempic and Wegovy. FDA said it was “not aware of any basis” for compounding with either salt that would satisfy federal rules on which raw ingredients compounders may use. That is agency language for no (a very polite no, but agencies are rarely rude in writing).&lt;&#x2F;p&gt;
&lt;p&gt;So here is the plain answer. Semaglutide sodium is semaglutide with a sodium group added, and semaglutide acetate is the same idea with an acetate group. The FDA-approved products, Ozempic and Wegovy, contain neither. They contain semaglutide base, the specific form that went through clinical trials and regulatory review. FDA’s position is that the salts are different active ingredients from the base, that it knows of no lawful way to compound with them under either section 503A or 503B of the law, and that it lacks information showing the salts share the base’s chemical and pharmacologic properties. No clinical studies exist confirming that the salts produce the same effects, absorption or safety profile as the base.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;why-semaglutide-sodium-counts-as-a-different-ingredient&quot;&gt;Why semaglutide sodium counts as a different ingredient&lt;&#x2F;h2&gt;
&lt;p&gt;The intuitive view is that semaglutide sodium is semaglutide with a little extra on it. That is the wrong way to think about it. Or rather, it is chemically sort of right and legally completely wrong, which is the stranger and more useful version. Adding a sodium or acetate group changes the molecule’s weight and how it dissolves, and potentially how the body absorbs and clears it. FDA treats the result as a different active ingredient. Not a variant. A different drug.&lt;&#x2F;p&gt;
&lt;p&gt;It is a bit like a backup quarterback taking the field in the starter’s jersey. The name on the back is right. The stats belong to someone else.&lt;&#x2F;p&gt;
&lt;p&gt;Here is a made-up phone call, to make the problem concrete:&lt;&#x2F;p&gt;
&lt;p&gt;“Hi, I’d like to order some semaglutide.”&lt;&#x2F;p&gt;
&lt;p&gt;“We have semaglutide sodium.”&lt;&#x2F;p&gt;
&lt;p&gt;“Is that semaglutide?”&lt;&#x2F;p&gt;
&lt;p&gt;“It says semaglutide on the label.”&lt;&#x2F;p&gt;
&lt;p&gt;Everything in that conversation is in some sense true, and the problem is that the approval system does not run on things being in some sense true. It runs on a specific molecule having been tested in specific trials. The base form is that molecule. The salts are not.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;the-three-doors-into-a-compounding-pharmacy&quot;&gt;The three doors into a compounding pharmacy&lt;&#x2F;h2&gt;
&lt;p&gt;A compounder cannot simply buy any powder and turn it into injections. Federal law says a bulk drug substance has to come through one of three doors. It can have a monograph in the United States Pharmacopeia or National Formulary (a monograph being an official published standard for what the substance is and how pure it must be). It can be a component of an FDA-approved drug. Or it can appear on FDA’s list of approved bulk substances, known as the bulks list.&lt;&#x2F;p&gt;
&lt;p&gt;Semaglutide, in any form, has no monograph. So door one is shut for everybody. Semaglutide base gets through door two, because it is a component of Ozempic and Wegovy. Being a component of an approved drug is, in compounding law, the sexiest thing an ingredient can be (it gets you into rooms). The sodium and acetate salts are not components of any approved drug, and neither appears on the bulks list. That is zero doors out of three.&lt;&#x2F;p&gt;
&lt;p&gt;There was a separate argument that the shortage changed things. Wegovy and Ozempic sat on FDA’s drug shortage list for a while, and the shortage list is what let compounders make copies at scale in the first place (the site’s article on the shortage covers how a drug gets on and off). But FDA clarified that the shortage listing “does not authorize” compounding semaglutide sodium or any other salt. The shortage loosened one rule. It did not loosen the ingredient rule. And after May 22, 2025, FDA prohibited distribution of compounded semaglutide and tirzepatide altogether, which made the salt question smaller without quite making it go away.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;three-ways-to-read-the-salt-form-episode&quot;&gt;Three ways to read the salt-form episode&lt;&#x2F;h2&gt;
&lt;p&gt;There are, roughly, three ways to read why salts showed up in compounded semaglutide at all, and they get progressively less comfortable.&lt;&#x2F;p&gt;
&lt;p&gt;The first reading is about supply. Novo Nordisk makes all approved semaglutide through its own semi-recombinant process, and it does not sell semaglutide base, or any form of the active ingredient, to compounding pharmacies. So compounders had to source from somewhere else. Where exactly, and why the salts in particular, the facts here do not settle. Presumably salts were what some suppliers had (supply chains are not famous for their sense of regulatory nuance). That’s fine as an explanation of how it happened. It is not an explanation that FDA accepts as a legal basis for anything.&lt;&#x2F;p&gt;
&lt;p&gt;The second reading is about rules. Some compounders presumably read the shortage as broad permission, or read “semaglutide” on a supply label as the end of the inquiry. FDA said otherwise in April 2023, and its published materials now include a section titled “Salt forms should not be used to compound semaglutide.” The Mississippi Board of Pharmacy told its licensees in writing that salt compounding does not meet FDA’s bulk substance requirements and could draw action from FDA or the board. Some compounders substituted the salts anyway, including after the injectable shortage ended. A pharmacy that dispenses a salt-form product labeled just “semaglutide” faces misbranding findings, board complaints and civil liability from patients who were not told. I don’t know how many did. The incentive to call it semaglutide is obvious, I guess: that is the word people are looking for.&lt;&#x2F;p&gt;
&lt;p&gt;The third reading is the uncomfortable one. It is that nobody knows whether the salt matters medically, and that not knowing is the whole problem. The approval system is a machine for converting a molecule into evidence. Semaglutide base went through the machine. The salts did not. America’s Poison Centers put it plainly: “some compounding pharmacies used different salt forms of semaglutide, which differ from the active ingredient found in FDA-approved semaglutide products.” Using the salt rather than the base creates greater potential for instability and variability, which can raise the risk of side effects or of the drug simply not working. Could a given salt product behave identically? Maybe. Nobody has run the study.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-the-absence-of-approval-data-actually-means&quot;&gt;What the absence of approval data actually means&lt;&#x2F;h2&gt;
&lt;p&gt;Here is a made-up scenario, pushed past reason. Suppose “semaglutide plus a small attachment” counted as semaglutide. Then semaglutide sodium is fine, and semaglutide acetate is fine, and semaglutide potassium, and semaglutide with a slightly larger attachment, and eventually semaglutide with a second, different peptide bolted on, or whatever. At some point you have a new drug that has never met a patient, and its only credential is that its name starts the right way. The rule that salts are different ingredients is dumb-sounding right up until you try to draw the line anywhere else.&lt;&#x2F;p&gt;
&lt;p&gt;Which is why FDA’s actual statements are so modest. The agency did not say the salts are dangerous. It said it lacks information showing they share the base’s properties, and it was not aware of any basis to compound with them. It barely raised its voice. That understatement carries the entire regulatory weight, because the default in drug law is not “allowed until proven harmful.” It is “not allowed until shown.”&lt;&#x2F;p&gt;
&lt;p&gt;The evidence gap is real and not just rhetorical. (My own research for this piece included losing an argument with a reCAPTCHA box that would not let me read a scientific paper on the subject, so the absence of data on semaglutide salts is something I have experienced at a personal level, which is not the most heroic form of journalism.) Several legal analyses of semaglutide compounding contain no specific evidence about the sodium or acetate formulations at all. That is not a gap someone forgot to fill. There is just nothing there.&lt;&#x2F;p&gt;
&lt;p&gt;I suppose the cleanest way to put it is that the salt question was never really about sodium. It was about which version of a molecule had a file. The base had a file. The salts did not.&lt;&#x2F;p&gt;
&lt;p&gt;It was semaglutide in every way except the ones that had been checked.&lt;&#x2F;p&gt;
</content>
        
    </entry>
    <entry xml:lang="en">
        <title>How Telehealth Weight-Loss Brands Built a Business on Compounders</title>
        <published>2026-11-01T00:00:00+00:00</published>
        <updated>2026-11-01T00:00:00+00:00</updated>
        
        <author>
          <name>
            
              Unknown
            
          </name>
        </author>
        
        <link rel="alternate" type="text/html" href="https://compoundglp.com/telehealth-and-compounding/"/>
        <id>https://compoundglp.com/telehealth-and-compounding/</id>
        
        <content type="html" xml:base="https://compoundglp.com/telehealth-and-compounding/">&lt;p&gt;Here is a small fact about the weight-loss shots sold by telehealth websites: the name on the vial is often the website’s own, and the pharmacy that actually made the drug is often not named at all. The FDA lists that practice, branding a product under the telehealth company’s name without saying which pharmacy compounded it, among the recurring problems in its warning letters to these companies. A drug that one business makes and another business names is not unusual (most store-brand cereal works this way). It gets more interesting when the drug is a prescription injection and the copy was legal only because of a shortage.&lt;&#x2F;p&gt;
&lt;p&gt;A compounded GLP-1 is a version of a drug like semaglutide or tirzepatide made by a compounding pharmacy instead of by the company that owns the approval. Federal law ordinarily forbids compounding copies of approved drugs, but a shortage exception built into sections 503A and 503B lets compounders fill the gap while a drug sits on the FDA’s official shortage list. The pharmacies made the product. The telehealth companies found the customers, wrote the ads and put their name on the box. This article is about that second half: the supply arrangement, the advertising rules, and the attention it all drew from regulators.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;who-gets-paid-when-a-compounded-glp-1-is-sold-online&quot;&gt;Who gets paid when a compounded GLP-1 is sold online&lt;&#x2F;h2&gt;
&lt;p&gt;Start with demand. The FDA approved Wegovy for weight loss in 2021, and Contrary Research calls that approval a key driver of the demand surge. Non-diabetic patients using GLP-1 drugs for weight loss went from 21,000 in 2019 to 174,000 in 2023. A survey in August 2025 found that nearly 12% of Americans had used a GLP-1 drug for weight loss at some point. That is a lot of people (it is also, to a marketing department, a very large audience). The manufacturers could not keep up, the drugs went on the shortage list, and the exception switched on.&lt;&#x2F;p&gt;
&lt;p&gt;Now the supply side. A compounding pharmacy is basically a business that is good at making sterile vials and, I assume, not especially good at search-engine advertising. A telehealth startup is the reverse: it has a checkout page, a marketing budget and a funnel full of people, and no drug. So the two hook up. It is a very discreet relationship, in the sense that only one of the partners is willing to be seen in public.&lt;&#x2F;p&gt;
&lt;p&gt;I imagine the founding conversation went something like this. “Hey, we have forty thousand people who clicked the ad and nothing to ship them,” says the growth lead. “We have a clean room and no website,” says the pharmacist. Everyone is doing their job well. The law firm ArentFox Schiff describes the result plainly: the compounded market “was fueled by telehealth startups and cash-pay obesity clinics.” At the 2024 peak, compounded versions reportedly accounted for up to 30% of total US GLP-1 supply.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;why-the-brand-wanted-its-own-name-on-the-vial&quot;&gt;Why the brand wanted its own name on the vial&lt;&#x2F;h2&gt;
&lt;p&gt;If you run the website, the customer relationship is the only thing you own. The drug is the pharmacy’s. The prescribing is a doctor’s. The molecule is, in some sense, Novo Nordisk’s or Eli Lilly’s. What you have is a logo, an email list and a monthly charge. If the vial says the pharmacy’s name in large letters, the customer starts to wonder what exactly the monthly charge is for. So the logo goes on the vial and the pharmacy goes behind the curtain, which is the Wizard of Oz business model with a sterile-compounding license.&lt;&#x2F;p&gt;
&lt;p&gt;Here is a made-up example to show where this leads. Imagine ten telehealth brands, each with its own color scheme and its own influencer, all quietly buying from the same pharmacy. A customer cancels one brand for a cheaper one and receives the identical vial with a different sticker. She cancels again, for a third brand with a nicer font. Same vial. Eventually all ten brands raise prices, the customer starts her own brand to buy from the same pharmacy, and the pharmacy now has eleven customers and one actual patient. The FDA, meanwhile, would have to write ten letters about one product. (I made all of this up, though the sticker part is roughly what the warning letters describe.)&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-the-advertising-rules-actually-say&quot;&gt;What the advertising rules actually say&lt;&#x2F;h2&gt;
&lt;p&gt;The FDA’s warning letters rest on two provisions of the Federal Food, Drug, and Cosmetic Act. Section 502(a) prohibits false or misleading drug labeling. Section 502(bb) is specific to compounding and prohibits false or misleading advertising or promotion of a compounded drug. The second one is the interesting one, because it exists for exactly this situation.&lt;&#x2F;p&gt;
&lt;p&gt;The obvious thing an advertiser wants to say is that the product is the famous drug, just cheaper. Between us, if you had to write the ad copy, you would want to say that too, because “Wegovy” is what the customer typed into the search bar. The FDA’s guidance to telehealth companies treats this as misbranding: describing a compounded product as a “generic version” of an approved drug, or “the same as” one, or “clinically proven” to match its results. A compounded drug is not a generic. It is a copy that was permitted because of a shortage, which is a different thing with a different legal basis.&lt;&#x2F;p&gt;
&lt;p&gt;The letters show how close to the line the copy got. FWD Care’s website claimed its compounded product shared the same active ingredient as brand-name GLP-1 drugs. Altru Telehealth’s website said its compounded semaglutide and tirzepatide contained an “FDA approved active ingredient,” which is a sentence built so that the word “approved” lands near the product without quite attaching to it. As for the Federal Trade Commission, the usual referee for advertising claims: the sources behind this article describe FDA letters, not FTC actions, so what the FTC has done here is not settled by them.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-changed-when-the-shortages-ended&quot;&gt;What changed when the shortages ended&lt;&#x2F;h2&gt;
&lt;p&gt;In February 2025 the FDA issued a Declaratory Order that the semaglutide shortage was resolved. Before doing so it gathered information from Novo Nordisk and also from patients, providers, compounders, outsourcing facilities and telehealth companies. It did something similar for tirzepatide, reviewing Lilly’s expanded capacity alongside submissions from, among others, telehealth companies. So the businesses whose legal basis depended on the shortage were asked whether the shortage was over (a question on which they had a fairly firm house view). I don’t know what they said. I can guess.&lt;&#x2F;p&gt;
&lt;p&gt;Alongside the order, the FDA posted an update titled “FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize.” Translated into one flat sentence: the real drug is available again, so the reason you were allowed to make copies is going away. Contrary Research reports that some compounders and direct-to-consumer platforms kept producing anyway, which drew scrutiny from the FDA and legal action from Novo Nordisk.&lt;&#x2F;p&gt;
&lt;p&gt;Then came the letters. One source says that on September 9, 2025, the FDA sent more than 50 warning letters to GLP-1 compounders and online sellers, citing misbranding under 502(a) and 502(bb). Pharmacy Times says that on September 16, 2025, it sent more than 55 to online sellers. One account lists three rounds to telehealth companies, in September 2025, February 2026 and June 2026; another says the FDA announced 30 letters on March 3, 2026, and that a third wave went out on June 8, 2026. A February 2026 letter cited sameness and branding problems over compounded liraglutide. (My job, it turns out, is mostly reconciling warning-letter counts that do not agree.) The rough shape is settled. The exact tally, from these sources, is not.&lt;&#x2F;p&gt;
&lt;p&gt;The FDA also moved upstream. On February 6, 2026, it announced steps to restrict GLP-1 active ingredients used in non-FDA-approved compounded products. That is the regulatory equivalent of stopping the party by cutting off the ice delivery.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;where-the-chain-ends-up&quot;&gt;Where the chain ends up&lt;&#x2F;h2&gt;
&lt;p&gt;Compounded semaglutide often comes in multi-dose vials, and the FDA has warned that different compounders may supply different concentrations. Its advice to health care providers who are unsure about a concentration is to contact the compounder. It also recommended giving patients the right syringe size for the intended dose. On July 29, 2025, the FDA warned of patients mistakenly giving themselves five to twenty times the intended dose and ending up in the hospital.&lt;&#x2F;p&gt;
&lt;p&gt;So follow the chain one more time. Demand created a shortage. The shortage created a legal opening for pharmacies. The pharmacies needed customers, the websites had customers, and the websites needed their own name on the vial so the customers would stay theirs. That meant the pharmacy’s name came off, or never went on. And the safety instruction for a confusing dose is: call the pharmacy.&lt;&#x2F;p&gt;
&lt;p&gt;The point is that the one fact the warning letters keep demanding, which pharmacy made this, is the fact the business was built to hide. After a boom in which compounded drugs reached as much as 30% of supply, the main lasting change to the vial may be that the supplier finally gets its name on it, in small print, under someone else’s logo.&lt;&#x2F;p&gt;
</content>
        
    </entry>
    <entry xml:lang="en">
        <title>USP 797: The Rulebook for Sterile Compounding</title>
        <published>2026-11-01T00:00:00+00:00</published>
        <updated>2026-11-01T00:00:00+00:00</updated>
        
        <author>
          <name>
            
              Unknown
            
          </name>
        </author>
        
        <link rel="alternate" type="text/html" href="https://compoundglp.com/usp-797-sterile-compounding/"/>
        <id>https://compoundglp.com/usp-797-sterile-compounding/</id>
        
        <content type="html" xml:base="https://compoundglp.com/usp-797-sterile-compounding/">&lt;p&gt;I spent part of this week reading the rules for how a pharmacy is supposed to make an injectable drug in a back room, and the strangest thing in them is a date. The rulebook is USP 797, a chapter of the United States Pharmacopeia that sets the standards for sterile compounding, and the date is the “beyond-use date,” the moment after which a vial of compounded medicine is supposed to stop being used. A great deal of the compounded GLP-1 story turns out to run through that date.&lt;&#x2F;p&gt;
&lt;p&gt;Here is the plain version. Pharmacies that compound for individual patients under section 503A “must comply with USP &amp;lt;795&amp;gt; and USP &amp;lt;797&amp;gt; along with state board of pharmacy regulations.” The revised versions of those chapters became final and enforceable on November 1, 2023. Outsourcing facilities under 503B answer to full federal CGMP rules on top of that, and the sterile chapters keep applying to them even while a drug is being wound down after a shortage. For an injectable, the standard covers clean rooms, how much drug the vial has to contain, and how long the vial is allowed to be a vial.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-usp-797-requires-starting-with-one-syringe&quot;&gt;What USP 797 requires, starting with one syringe&lt;&#x2F;h2&gt;
&lt;p&gt;Start small. A pharmacist makes one injection for one patient. That is the original 503A picture: compounding “according to prescriptions specific to particular patients,” dispensed for home use. You want three things from that injection. It should not have bacteria in it. It should contain about the amount of drug the label says. And it should get used before it goes bad.&lt;&#x2F;p&gt;
&lt;p&gt;The second one has a number. According to the Rx.com potency guide, “USP sets a minimum potency threshold of 90% of label strength for sterile injectables,” and the full range is 90% to 110%. So a vial labeled at some strength can be a tenth light or a tenth heavy and still pass (a tolerance roughly as generous as the one most people apply to a recipe). That is the rule.&lt;&#x2F;p&gt;
&lt;p&gt;The first one is the clean room, which is where the chapter’s paperwork lives. An FDA warning letter sent on September 18, 2026, to a Houston compounding pharmacy cited “inadequate smoke studies and rewritten media fill records” among its sterile compounding failures. (I will not pretend to explain the engineering of a smoke study from memory.) The point is that sterility is mostly proven with records, and records can be rewritten.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;beyond-use-dates-or-how-long-a-vial-gets-to-exist&quot;&gt;Beyond-use dates, or how long a vial gets to exist&lt;&#x2F;h2&gt;
&lt;p&gt;The third thing is the date. The beyond-use date is basically an expiration date. Actually, that is not quite it. An expiration date sort of implies someone tested the product and found out when it degrades, while a 503A pharmacy may rely on default BUD categories set out in the chapter. The date can come from a chart rather than from the drug.&lt;&#x2F;p&gt;
&lt;p&gt;This is reasonable, from where the pharmacist stands. If you make one syringe for one person, running a stability study on that exact formulation is presumably not something anyone does, so a conservative default does the job. The patient wants the shot, the pharmacist wants a date that is defensible, and the chapter supplies one. Everyone is acting sensibly.&lt;&#x2F;p&gt;
&lt;p&gt;(I feel like every article I write eventually becomes an article about a date on a label, which says something about the job.)&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-the-2023-revision-changed-as-far-as-the-facts-go&quot;&gt;What the 2023 revision changed, as far as the facts go&lt;&#x2F;h2&gt;
&lt;p&gt;The revised USP &amp;lt;795&amp;gt;, &amp;lt;797&amp;gt; and &amp;lt;800&amp;gt; reached final enforceable status on November 1, 2023. That much is settled. The facts I have do not lay out clause by clause what the revision changed in the clean-room rules or the default dating tables, so I am not going to invent them. What is clear is that “enforceable” depends on who is enforcing.&lt;&#x2F;p&gt;
&lt;p&gt;Kentucky, for instance, began active enforcement of the revised chapters on January 1, 2026. That is a bit over two years after the standards became final. So in some places the 2023 rules were, for a while, the 2023 rules in the way a gym membership is a fitness plan.&lt;&#x2F;p&gt;
&lt;p&gt;States enforce the chapter through licensing, which is how it gets teeth. Washington and Ohio now require verifiable PCAB accreditation before a nonresident compounding pharmacy can get licensed there. Federal law adds its own layer: ingredients used in 503A compounding have to meet an applicable USP or NF monograph if one exists, plus “the USP chapter on pharmacy compounding.”&lt;&#x2F;p&gt;
&lt;h2 id=&quot;scaling-up-to-a-batch-and-then-to-a-business&quot;&gt;Scaling up to a batch, and then to a business&lt;&#x2F;h2&gt;
&lt;p&gt;Now escalate. Instead of one syringe, the pharmacist makes twenty a day for twenty patients. Same rules. Fine.&lt;&#x2F;p&gt;
&lt;p&gt;Now it is hundreds a week, because a drug is short and demand is enormous (which is the usual way a small pharmacy finds out it is a large one). This happened. Compounders entered the GLP-1 market in 2022 when semaglutide and tirzepatide went on the FDA shortage list, and the shortage exception let them make copies they ordinarily could not. Each vial still needs its date. Each date can still come from the default table.&lt;&#x2F;p&gt;
&lt;p&gt;Now it is a large batch, made without patient-specific prescriptions, shipped to clinics for office use. That is a 503B outsourcing facility, and at this scale the FDA stops being comfortable with the chart. Its draft CGMP guidance expects beyond-use dates “to be supported by formulation-specific stability data, rather than the default BUD categories a 503A pharmacy may rely on.” Which is also sensible: a guess applied to one vial is a guess, but a guess applied to a whole batch is a business model.&lt;&#x2F;p&gt;
&lt;p&gt;The FDA’s view, presumably, is that if you are making stuff by the thousand you can afford to test it. The facility’s view is that it is following the rules for its category. Both are correct about their own category, which is the whole problem.&lt;&#x2F;p&gt;
&lt;p&gt;Then add ingredients. A 2025 survey of compounded GLP-1 products found 33 unique semaglutide and tirzepatide products, 48% of them combined with other things (cyanocobalamin, glycine, niacinamide, docusate, ondansetron, etc.). Every combination is a new formulation. Each one would need its own stability data to have a tested date. The same survey found that only 18% of products provided beyond-use-date information at all. So the date that the whole system relies on was, in most cases, not visible to the person holding the vial.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;how-far-along-the-road-we-already-are&quot;&gt;How far along the road we already are&lt;&#x2F;h2&gt;
&lt;p&gt;Here is the absurd endpoint of the escalation. Suppose the shortage ends. The legal permission to compound copies disappears, but the vials already made do not. What decides when the old regime is finally over?&lt;&#x2F;p&gt;
&lt;p&gt;The date on the vial does. Consider this invented scene at a pharmacy counter: “Hey, the shortage ended in February, but this batch is good until its BUD, so technically we are still in the shortage until Thursday.” Sounds dumb. It is also, more or less, the rule.&lt;&#x2F;p&gt;
&lt;p&gt;The guide titled Compounding After a Drug Leaves the Shortage List says product compounded and dispensed before the enforcement deadline “can generally still be used through its assigned beyond-use date, but new compounding after the window closes is not permitted.” The FDA resolved the semaglutide injectable shortage on February 21, 2025, and gave 503A pharmacies until April 22 and 503B facilities until May 22 to stop compounding under the exception. After that, the tail of the shortage is measured in beyond-use dates, like the milk in your fridge outliving the grocery store that sold it.&lt;&#x2F;p&gt;
&lt;p&gt;And then there is the part of the market that skips the chapter entirely. Online stores selling “GLP-1 research solutions” not compounded in USP &amp;lt;797&amp;gt; clean rooms are frequently named in FDA warning letters. The boundary between a research solution and a weekly routine in the bathroom mirror is, let us say, blurry. Those products have no default category and no stability data. Lol.&lt;&#x2F;p&gt;
&lt;p&gt;So the escalation is not hypothetical. One syringe became batches, batches became combinations, combinations mostly lost their dates, and the date became the clock on the end of a federal shortage. The most durable piece of the semaglutide shortage, legally speaking, may have been a number a 503A pharmacist looked up in a default table and wrote on a label.&lt;&#x2F;p&gt;
</content>
        
    </entry>
    <entry xml:lang="en">
        <title>How to Check a Compounding Pharmacy Near You Is Legitimate</title>
        <published>2026-11-01T00:00:00+00:00</published>
        <updated>2026-11-01T00:00:00+00:00</updated>
        
        <author>
          <name>
            
              Unknown
            
          </name>
        </author>
        
        <link rel="alternate" type="text/html" href="https://compoundglp.com/verify-a-compounding-pharmacy/"/>
        <id>https://compoundglp.com/verify-a-compounding-pharmacy/</id>
        
        <content type="html" xml:base="https://compoundglp.com/verify-a-compounding-pharmacy/">&lt;p&gt;There are two ways to find out whether a compounding pharmacy is legitimate, and they end up in roughly the same place. The quick way is to type “compounding pharmacy near me” into a search engine, click a result, and notice that it has a storefront, a phone number and a pharmacist with a name tag. The slow way is to confirm the pharmacy’s license with the state board of pharmacy, work out whether it is a 503A pharmacy or a 503B outsourcing facility, check for optional accreditation, look for FDA warning letters, and ask what exactly is going into the vials.&lt;&#x2F;p&gt;
&lt;p&gt;The slow way produces a plain answer. For an ordinary neighborhood compounder, legitimacy mostly means a state license. Federal law lets a 503A pharmacy compound when the work is done by a licensed pharmacist in a state-licensed pharmacy (or a federal facility, or by a licensed physician). These pharmacies are regulated primarily by state boards rather than the FDA, and they are not required to register with the FDA at all. So the license is the thing, the state board is where it lives, and most of the rest of the checking is about what a licensed pharmacy is doing with that license.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-a-search-for-a-compounding-pharmacy-near-you-turns-up&quot;&gt;What a search for a compounding pharmacy near you turns up&lt;&#x2F;h2&gt;
&lt;p&gt;It turns up a lot, and the reason is GLP-1s. Compounders entered that market in 2022, when demand for semaglutide and tirzepatide outran supply and both drugs went onto the FDA Drug Shortage List. The law firm ArentFox Schiff describes what followed as a “multibillion-dollar sub-industry,” which is a nice way of saying that a corner of pharmacy built mostly for odd doses and allergy-free formulations suddenly found itself in the weight-loss business. At the 2024 peak, nearly 1 in 3 Americans taking a GLP-1 said they got it from a compounding pharmacy.&lt;&#x2F;p&gt;
&lt;p&gt;The legal basis for all that was narrow. Copying an FDA-approved drug is ordinarily prohibited. The exception in sections 503A and 503B allows a copy only while the approved product is on the shortage list “at the time of compounding, distribution, and dispensing” (all three, not just one of them). The shortage was the whole permission slip.&lt;&#x2F;p&gt;
&lt;p&gt;Then the slip expired. The FDA issued a declaratory order on February 21, 2025 resolving the semaglutide injectable shortage, and gave 503A pharmacies until April 22, 2025 and 503B outsourcing facilities until May 22, 2025 to stop compounding under the shortage exception. The search results did not all get the memo at the same speed. (Search results rarely do.)&lt;&#x2F;p&gt;
&lt;h2 id=&quot;the-dumb-version-the-sign-on-the-wall&quot;&gt;The dumb version: the sign on the wall&lt;&#x2F;h2&gt;
&lt;p&gt;The dumb version of checking legitimacy is to look at the pharmacy and conclude that it looks like a pharmacy. It has a counter. It has a pharmacist who says, “Hey, yes, we’re fully licensed, it’s on the wall right there.” It has a website with a photo of someone in gloves holding a vial up to the light, which is the universal sign for science.&lt;&#x2F;p&gt;
&lt;p&gt;I mean, this is roughly how everyone picks a restaurant. There is a health inspection grade taped in the window, and people mostly trust that it was earned and that it still applies. That trust is usually correct.&lt;&#x2F;p&gt;
&lt;p&gt;The point is that the dumb version is not crazy. A pharmacy with a real address and a pharmacist answering the phone is, most of the time, a pharmacy holding a real state license, because operating one without a license is the kind of thing that tends to come up (usually at an inconvenient moment for the operator).&lt;&#x2F;p&gt;
&lt;h2 id=&quot;the-sophisticated-version-the-state-board-then-everything-else&quot;&gt;The sophisticated version: the state board, then everything else&lt;&#x2F;h2&gt;
&lt;p&gt;The sophisticated version starts at the same wall but takes the certificate down and checks it. The state board of pharmacy issued the license, so the board is the authority on whether the license exists and is in good standing. For a 503A pharmacy, that is close to the whole regulatory picture: such pharmacies must follow USP &amp;lt;795&amp;gt; and USP &amp;lt;797&amp;gt; (the sterile one) plus state rules, and a pharmacy compounding for a specific patient’s prescription is exempt from the federal CGMP framework in 21 CFR Parts 210 and 211.&lt;&#x2F;p&gt;
&lt;p&gt;Next comes the question of which kind of compounder this is, because the word “pharmacy” covers two very different animals. A 503B outsourcing facility can compound large volumes from bulk ingredients without individual prescriptions, and in exchange it must meet CGMP, the manufacturing rulebook, on top of state requirements. So the FDA is the more natural place to ask about a facility that claims 503B status, and the state is the place to ask about the neighborhood shop. A storefront that describes itself both ways is describing something.&lt;&#x2F;p&gt;
&lt;p&gt;Then there are the optional extras. The Pharmacy Compounding Accreditation Board offers third-party accreditation. Optional is doing real work in that sentence. Accreditation tells you the pharmacy volunteered to be looked at, which is information, though it is information about the pharmacy’s appetite for inspection rather than about any particular vial.&lt;&#x2F;p&gt;
&lt;p&gt;Then there are warning letters, which are where the FDA writes down, in public, what it found. And here the sophisticated version picks up some odd results, because the parties named are not always pharmacies. FDA warning letters to telehealth companies have named the platform itself, and not just the compounder behind it, as the party responsible for misbranding. So a patient might check the pharmacy carefully and the problem might be the website that sent the prescription there.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-the-red-flags-in-the-paperwork-look-like&quot;&gt;What the red flags in the paperwork look like&lt;&#x2F;h2&gt;
&lt;p&gt;The most famous red flag is a chemistry question that turns out to be a legal one. Federal law gives a bulk ingredient in 503A compounding three ways to be lawful: it meets a USP or NF monograph, it is a component of an FDA-approved drug, or it appears on an FDA-developed list. Semaglutide sodium and semaglutide acetate fail all three. On April 27, 2023, the FDA told the National Association of Boards of Pharmacy that it was “not aware of any basis” for compounding with those salt forms that would satisfy federal requirements. The Mississippi Board of Pharmacy then told its licensees in writing that salt compounding may draw action “from FDA or the board itself.” (The other articles on this site go into why the salt matters; here it matters because it is written down.)&lt;&#x2F;p&gt;
&lt;p&gt;This is the place where the two versions diverge most sharply, at least on paper. A pharmacy can hold a spotless license and still be making the thing the licensing system has said it should not make. The license is about the pharmacy. The salt is about the product.&lt;&#x2F;p&gt;
&lt;p&gt;The second kind of red flag shows up in what inspectors write. On September 18, 2026, the FDA sent a warning letter to a Houston compounding pharmacy citing “pretextual significant-difference determinations.” Translated: the pharmacy said its version was different from the approved drug so it could keep making it, and the FDA did not believe the difference was real. The same letter cited “boilerplate prescribing records,” which is prescriptions that all look suspiciously alike, and “rewritten media fill records,” which is the sterile-compounding version of finding that someone has gone back and edited the diary. It also cited “inadequate smoke studies,” a phrase that makes the clean room sound like it has been having a more interesting weekend than the paperwork admits, and that refers, I assume, to something much duller involving air.&lt;&#x2F;p&gt;
&lt;p&gt;The third kind of red flag is the shortage calendar itself. If a drug is no longer on the list, the copying exception is gone, and a pharmacy still advertising a copy is relying on something else. Sometimes that something else is a claimed significant difference. See above.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;where-both-versions-end-up&quot;&gt;Where both versions end up&lt;&#x2F;h2&gt;
&lt;p&gt;Here is a scenario, entirely made up. A patient runs the full sophisticated version on a pharmacy. The state board confirms an active license. The pharmacy is plainly 503A and says so. It is accredited. No warning letters. She then calls and asks which salt form they use, and the pharmacist, to be fair, answers honestly. She asks to see the media fill records, and they show her. She asks about smoke studies, and they invite her in to watch. By week three she is spending more time in the clean room than the technicians, and the board offers her a job, and now she is the one doing the license checks.&lt;&#x2F;p&gt;
&lt;p&gt;And what did she learn? Mostly that the pharmacy was licensed by the state. Which is what the sign said.&lt;&#x2F;p&gt;
&lt;p&gt;On the other hand, the long road does buy something the short one cannot: the questions about the product. The license answers whether this business may compound. The salt letter, the shortage dates and the warning letters answer whether this particular compounding is the kind the rules allow. Those are different questions, and only one of them is printed on the wall. You and I both know which one gets searched for.&lt;&#x2F;p&gt;
&lt;p&gt;There is also a gap neither version closes. In a 2023 case series of compounded semaglutide errors reported to a poison control center, one patient got a vial and syringes for self-administration with no pharmacist counseling on how to use them. A license lookup does not tell you whether anyone will explain the syringe. It’s fine; that is not what a license lookup is for. Anyway, the most thorough possible check of a compounding pharmacy ends at a licensed professional who has to be trusted to do the job right, which is also where the quickest possible check ends, so the truly sophisticated move would be to check the pharmacist’s license, and then the license of whoever checked that.&lt;&#x2F;p&gt;
</content>
        
    </entry>
    <entry xml:lang="en">
        <title>What Is a Compounding Pharmacy, and Why Did It Become a Weight-Loss Business?</title>
        <published>2026-11-01T00:00:00+00:00</published>
        <updated>2026-11-01T00:00:00+00:00</updated>
        
        <author>
          <name>
            
              Unknown
            
          </name>
        </author>
        
        <link rel="alternate" type="text/html" href="https://compoundglp.com/what-is-a-compounding-pharmacy/"/>
        <id>https://compoundglp.com/what-is-a-compounding-pharmacy/</id>
        
        <content type="html" xml:base="https://compoundglp.com/what-is-a-compounding-pharmacy/">&lt;p&gt;A compounding pharmacy is a pharmacy where somebody still makes the medicine. Most pharmacies count pills that a manufacturer made in a factory, put them in an orange bottle and type a label. A compounder takes raw ingredients and mixes a drug for one particular patient, because the factory version does not fit that patient. Maybe it has a dye they are allergic to, or it only comes as a pill and they cannot swallow pills.&lt;&#x2F;p&gt;
&lt;p&gt;That is the traditional answer to what is a compounding pharmacy, and it is still the legal answer. The practical answer changed around 2022, when compounders started making copies of the new weight-loss drugs for a large share of the country. At peak in 2024, nearly 1 in 3 Americans taking a GLP-1 drug reported getting it from a compounding pharmacy. That is a lot of custom work. How a business built for the patient who cannot swallow pills ended up supplying a third of a national drug craze is a story about who gets paid for what, one link at a time.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-is-a-compounding-pharmacy-supposed-to-do&quot;&gt;What is a compounding pharmacy supposed to do?&lt;&#x2F;h2&gt;
&lt;p&gt;Federal law, in Section 503A of the drug statute, allows patient-specific compounding “by a licensed pharmacist in a State licensed pharmacy or a Federal facility, or by a licensed physician.” The key words are patient-specific. There is a prescription, it names a person, and the pharmacist makes that person’s drug.&lt;&#x2F;p&gt;
&lt;p&gt;Because it is one drug for one person, it gets a lighter rulebook. A 503A pharmacy compounding for a patient-specific prescription is exempt from the federal current good manufacturing practice rules that drug factories follow. These pharmacies are regulated mainly by state boards of pharmacy, not the FDA, and they do not have to register with the FDA. This makes sense. You do not want to inspect a pharmacist’s mortar and pestle like it is a plant producing a billion tablets (the mortar would not survive the audit).&lt;&#x2F;p&gt;
&lt;p&gt;The rulebook does have a line, though, and Wikipedia states it plainly. Making compounded medicines in advance batches, rather than for a specific person on demand, is called “non-traditional” or “officinal” compounding, and it “is akin to small-scale manufacturing.” Keep that word “manufacturing” in mind. The whole story is about how small “small-scale” stays.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;why-the-law-lets-a-pharmacist-copy-a-branded-drug-at-all&quot;&gt;Why the law lets a pharmacist copy a branded drug at all&lt;&#x2F;h2&gt;
&lt;p&gt;Ordinarily it doesn’t. Compounding a copy of an FDA-approved drug is ordinarily prohibited, which also makes sense: if a factory makes a drug the FDA approved, a pharmacist mixing the same drug in the back room is not serving a special patient. It is just competing with the factory, with fewer inspections.&lt;&#x2F;p&gt;
&lt;p&gt;The exception is a shortage. If the approved drug is on the FDA’s drug shortage list, compounders may make it, on the theory that a patient who needs a drug the factory cannot supply has a pretty special need. Semaglutide and tirzepatide went on that list in 2022, when demand outran supply, and compounding pharmacies entered the market. One account of the period puts it bluntly: the shortage-list exception, “not any general right to compound popular medications,” is what allowed large-scale compounding of these drugs for several years.&lt;&#x2F;p&gt;
&lt;p&gt;So the legal machinery was simple. Factory can’t keep up, pharmacist fills the gap, gap closes, pharmacist goes back to the patient who can’t swallow pills. It’s fine. It is the sort of rule that works well when the gap is small.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;how-a-shortage-turned-the-exception-into-a-supply-chain&quot;&gt;How a shortage turned the exception into a supply chain&lt;&#x2F;h2&gt;
&lt;p&gt;The gap was not small. The FDA approved Wegovy for weight loss in 2021, which helped drive a demand surge. Non-diabetic patients using GLP-1 drugs for weight loss went from 21,000 in 2019 to 174,000 in 2023, an increase of more than 700%. By August 2025, a survey found nearly 12% of Americans had used a GLP-1 for weight loss at some point.&lt;&#x2F;p&gt;
&lt;p&gt;Now follow the chain. A patient wants the drug and cannot find the branded version, or cannot afford it. A telehealth company sees the patient and gets paid for the visit (and, often, for a monthly subscription). A prescriber on the platform writes a prescription. A compounding pharmacy gets paid for each vial. Each link is doing something individually legal, and each link earns more the more patients go through.&lt;&#x2F;p&gt;
&lt;p&gt;It is easy to picture the conversation at some startup, which I am inventing: “Hey guys, the pharmacy is technically making a custom drug for each patient. What if each patient was the same patient, but more of them?” Nobody needs to say this out loud. The incentive says it.&lt;&#x2F;p&gt;
&lt;p&gt;The relationships got a little blurry. A visit, a prescription, a vial, a dosing chart, a sleek box, an automatic refill, a referral bonus. At some point the patient is not sure whether they have a doctor, a pharmacy or a subscription box, and the honest answer may be all three. To be fair, the FDA noticed: its warning letters to telehealth companies name the platform itself, not just the pharmacy, as responsible for misbranding the drug.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;when-a-pharmacy-starts-working-like-a-factory&quot;&gt;When a pharmacy starts working like a factory&lt;&#x2F;h2&gt;
&lt;p&gt;Here is where the second meaning of “small-scale manufacturing” kicks in. A pharmacy built around one patient at a time was now producing for a third of a market, under rules written for one patient at a time. Those rules were not designed to answer factory questions, and the results were weird in the specific way factory problems are weird.&lt;&#x2F;p&gt;
&lt;p&gt;For instance, a pharmacovigilance study of the FDA’s adverse event reporting system compared compounded GLP-1 products to non-compounded ones. The reporting odds ratio for preparation errors was 48.92. Not 48, not 50. 48.92. I find it hard to look away from that number. It says that, among the reports in that database, preparation errors showed up in compounded products at roughly forty-nine times the rate you would expect from the comparison drugs, measured to two decimal places, which is the kind of precision usually reserved for things that are going well. Contamination came in at 19.00 and compounding or manufacturing issues at 8.51. (A reporting ratio measures what people report, not a precise count of what happened, which the people who run these studies will tell you at length.)&lt;&#x2F;p&gt;
&lt;p&gt;Then there is the packaging. A factory pen clicks to a dose. A compounded vial comes with syringes and math. A 2023 case series of poison control calls described one patient who got a vial and syringes for self-administration “with no pharmacist counseling provided on proper drug administration.” America’s Poison Centers report a nearly 1,500% increase since 2019 in calls about overdoses or side effects of injectable weight-loss drugs. A vial plus syringes is, in everyday-life terms, a bit like being handed the flour and a recipe in a unit you have never used. (Here is where I admit my qualifications: I read warning letters for a living and have never mixed anything more sterile than a vinaigrette.)&lt;&#x2F;p&gt;
&lt;p&gt;I mean, the money got large too. The U.S. compounding pharmacy market was valued at roughly $6.98 billion in 2025 and is projected to reach $12.79 billion by 2035. The projection assumes 6.24% annual growth, which, for an industry that just went through what this one went through, is a strikingly calm number.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-happens-when-the-shortage-ends&quot;&gt;What happens when the shortage ends&lt;&#x2F;h2&gt;
&lt;p&gt;The exception was tied to the shortage, so when the drugs came off the shortage list, the exception was supposed to go with them. (The site covers the delistings in detail elsewhere.) On the other hand, a business that has customers, payroll and a refill schedule does not simply stop. It looks for a new reason.&lt;&#x2F;p&gt;
&lt;p&gt;One reason is that a compounder may still make a drug for a patient who needs a significant difference from the branded product. That is the original purpose of compounding, still sitting in the law. Which brings us to a warning letter the FDA sent on September 18, 2026, to a Houston compounding pharmacy, citing “pretextual” significant-difference determinations, boilerplate prescribing records, and sterile compounding failures including inadequate smoke studies and rewritten media fill records. The same day, BioSpace reported, the FDA sent a warning letter to Empower Clinic Services, doing business as Empower Pharmacy, over risk of contaminating drugs “with filth.”&lt;&#x2F;p&gt;
&lt;p&gt;There are two ways to read this. One is that the chain bent the law: a rule written for the allergic patient got stretched to cover a mass market, and boilerplate is what stretching looks like on paper. The other is that the law did exactly what it said. A shortage happened, the statute said pharmacies could fill it, they filled it, and the trouble is that “fill the gap” never specified a maximum gap. Both readings fit the same facts. The documents do not settle which one is right.&lt;&#x2F;p&gt;
&lt;p&gt;Anyway, the FDA is also closing the bigger door. According to ArentFox Schiff, a May 2026 proposal, if finalized, would “close the last remaining regulatory pathway for large-scale compounding” of semaglutide, tirzepatide and liraglutide by 503B outsourcing facilities (the larger, FDA-registered kind of compounder, covered in their own article here). Whether it is finalized is not settled.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;where-the-chain-ended-up&quot;&gt;Where the chain ended up&lt;&#x2F;h2&gt;
&lt;p&gt;Look, nobody set out to turn the neighborhood compounding pharmacy into a weight-loss manufacturer. The patient wanted a drug. The platform wanted the visit fee. The prescriber wanted to help. The pharmacy wanted to sell vials. The law wanted to cover a shortage. Each wish was reasonable, and added together they produced a factory regulated as a workshop.&lt;&#x2F;p&gt;
&lt;p&gt;The workshop is now being asked to be a workshop again, for patients who are each, individually and on paper, different. If you run a compounding pharmacy and want to stay in the weight-loss business, you had better make sure every patient’s significant difference is both significant and different.&lt;&#x2F;p&gt;
</content>
        
    </entry>
</feed>
